US20110036352A1 - Method and apparatus for providing positive airway pressure to a patient - Google Patents

Method and apparatus for providing positive airway pressure to a patient Download PDF

Info

Publication number
US20110036352A1
US20110036352A1 US12/905,230 US90523010A US2011036352A1 US 20110036352 A1 US20110036352 A1 US 20110036352A1 US 90523010 A US90523010 A US 90523010A US 2011036352 A1 US2011036352 A1 US 2011036352A1
Authority
US
United States
Prior art keywords
pressure
flow
patient
gas
airway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/905,230
Inventor
Mark C. Estes
John Fiore
Douglas M. Mechlenburg
Heather Ressler
Jeff Kepler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Respironics Inc
Original Assignee
RIC Investments LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/253,496 external-priority patent/US5535738A/en
Priority claimed from US08/679,898 external-priority patent/US5794615A/en
Priority claimed from US09/041,195 external-priority patent/US6105575A/en
Application filed by RIC Investments LLC filed Critical RIC Investments LLC
Priority to US12/905,230 priority Critical patent/US20110036352A1/en
Publication of US20110036352A1 publication Critical patent/US20110036352A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0051Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes with alarm devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0057Pumps therefor
    • A61M16/0066Blowers or centrifugal pumps
    • A61M16/0069Blowers or centrifugal pumps the speed thereof being controlled by respiratory parameters, e.g. by inhalation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/021Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
    • A61M16/022Control means therefor
    • A61M16/024Control means therefor including calculation means, e.g. using a processor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/20Valves specially adapted to medical respiratory devices
    • A61M16/201Controlled valves
    • A61M16/202Controlled valves electrically actuated
    • A61M16/203Proportional
    • A61M16/204Proportional used for inhalation control
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/20Valves specially adapted to medical respiratory devices
    • A61M16/201Controlled valves
    • A61M16/202Controlled valves electrically actuated
    • A61M16/203Proportional
    • A61M16/205Proportional used for exhalation control
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0057Pumps therefor
    • A61M16/0066Blowers or centrifugal pumps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/0015Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
    • A61M2016/0018Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical
    • A61M2016/0021Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical with a proportional output signal, e.g. from a thermistor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/0027Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A61M2016/0033Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
    • A61M2016/0036Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the breathing tube and used in both inspiratory and expiratory phase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A61M2016/0033Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
    • A61M2016/0039Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the inspiratory circuit

Definitions

  • the present invention relates generally to methods and apparatus for treating breathing and/or cardiac disorders and, more particularly, to methods and apparatus for providing a pressure to an airway of a patient during at least a portion of the breathing cycle to treat obstructive sleep apnea syndrome, chronic obstructive pulmonary disease, congestive heart failure, and other respiratory and/or breathing disorders.
  • CPAP Continuous positive airway pressure
  • OSAS obstructive sleep apnea syndrome
  • OSAS obstructive sleep apnea syndrome
  • CPAP Continuous positive airway pressure
  • CPAP a constant splinting pressure
  • CPAP a simple solution to the problem posed by the collapsing airway.
  • this approach exposes the patient to pressures that are higher than the pressures needed to support the airway for most of the breathing cycle.
  • CPAP levels are typically set to raise the pressure level in the entire respiratory system to the level required to both eliminate the sub-ambient pressures generated by inspiration and overcome any mechanical collapsing forces that result from the structure of the airway tissues, muscle tone, and body position.
  • the inspiratory pressures i.e., inspiratory positive airway pressure or “IPAP,” in bi-level positive airway pressure systems are set in a similar manner.
  • a positive pressure gradient exists between the interior of the lungs and the exterior of the body. This positive pressure gradient helps to support the airway during exhalation. At the end of exhalation, the pressure gradient is essentially zero; flow is likewise zero and the airway is unaffected by respiratory efforts. Any collapse of the airway at the end of exhalation is purely a function of the structure of the airway tissues, muscle tone, and body position. Bi-level devices seek to supply the expiratory pressure required to support the airway at the end of exhalation.
  • the pressure gradients between the lungs and the exterior of the body are not constant.
  • the inspiratory pressure gradient falls from zero at the start of inspiration to a peak negative value and then rises back to zero at the end of inspiration.
  • the expiratory pressure gradient rises from zero at the start of exhalation to a peak value and then falls back to zero as exhalation ends. Because the pressure gradient varies over the breathing cycle, the pressure necessary to overcome airway collapse should ideally vary over the breathing cycle.
  • CPAP therapy ignores these variations in pressure requirements and provides therapy at one pressure level.
  • Conventional CPAP is rather crude and offers far from optimal therapy since the CPAP pressure is based solely on a worst-case treatment parameter, i.e., the peak pressure requirements during inspiration.
  • bi-level positive airway pressure (bi-level PAP) therapies seek to take advantage of the different pressure requirements to lower the pressure during exhalation. Nevertheless, bi-level therapies also fail to afford optimal treatment because the inspiratory positive airway pressure (IPAP) of bi-level PAP is again based on the patient's peak needs encountered during inspiration and remains constant over the entire inspiratory phase respiration. Also, during bi-level treatment, the expiratory position airway pressure (EPAP) remains constant and is related solely to the support needs at the end of exhalation.
  • IIPAP inspiratory positive airway pressure
  • EEPAP expiratory position airway pressure
  • a COPD patient in order to begin inspiratory flow, a COPD patient must reduce the pressure inside his lungs to a pressure that is less than the ambient pressure at the inlet of his respiratory system. Due to the condition commonly known as “Auto-PEEP,” the pressure in the patient's lungs is typically above ambient pressure at the end of exhalation. The patient's breathing muscles thus must perform additional work to expand the lungs and thereby reduce lung pressure below ambient before flow into the lungs can occur. Auto-PEEP is typically treated with a form of resistive counter pressure known as PEEP (positive end expiratory pressure). PEEP is set at a level just below the patient's Auto-PEEP level, thereby reducing the amount of breathing work required to initiate inspiratory flow.
  • PEEP positive end expiratory pressure
  • EPAP indicates a constant pressure delivered to the patient throughout exhalation, while PEEP indicates positive end expiratory pressure.
  • PEEP indicates positive end expiratory pressure.
  • the PEEP pressure is only required at the end of exhalation.
  • iron lung An early example of such a system, commonly referred to as an “iron lung,” is disclosed in a publication entitled “Mechanical Assistance to Respiration in Emphysema, Results with a Patient-Controlled Servorespirator,” authored by James R. Harries, M.D. and John M. Tyler, M.D., published in the American Journal of Medicine, Vol. 36, pp. 68-78, January 1964.
  • the iron lung proposed in that publication is a respirator designed to apply and remove transthoracic pressure to and from the exterior surface of the body of a subject who sits in a large pressurizable chamber in order to assist the patient's respiratory efforts (i.e., the iron lung applies negative pressure during inspiration and either ambient or positive pressure during expiration).
  • the apparatus continually controlled the internal chamber pressure in response to the patient's spontaneous respiration, specifically in response to detected respiratory flow or volume.
  • a signal obtained from a strain gauge pneumograph fastened around the patient's chest was electrically separated into three components: one proportional to volume, another to inspiratory flow and a third to expiratory flow. Each component was assigned a separate gain control. The component signals are then recombined to control the pressure in the chamber by means of an electrically driven variable valve situated between a blower and the chamber.
  • iron lung devices Although effective for their intended purposes, this and other iron lung devices have generally fallen into disfavor because of their bulk, inconvenience, cost and limited application. That is to say, because of their size and cost such equipment is purchased and maintained essentially exclusively by medical facilities such as hospitals and clinics. Further, iron lungs do not lend themselves to treatment of OSAS and related disorders where comfort and unobtrusiveness are critical for patient compliance and treatment efficacy. This is because negative pressure applied during inspiration compounds the factors that operate to collapse the airway during an inspiratory phase.
  • the system may load or unload during inspiration, expiration, or both, to assist or resist a subject's spontaneous respiratory activity.
  • the system may apply a continuous positive or negative pressure directly to the subject's airway and loading or unloading occurs via a command signal generated by detected respiratory flow, volume, applied voltage, an external function, or other source.
  • a drawback to this system is that a single resistive gain is chosen for resistive loading or unloading.
  • This single gain is applied to a “half-wave” of the respiratory cycle (either inspiration or expiration) or the “full-wave” thereof (both inspiration and expiration).
  • a single chosen gain value is employed during both inspiration and expiration.
  • the constant proportion is achieved by (1) selecting a desired gain for a detected positive mouth pressure signal, (2) calculating the ratio of the gain-modified mouth pressure signal over a detected signal reflecting instantaneous flow, (3) comparing the calculated ratio to a selected reference ratio to generate a valve motor control signal, and (4) using the valve motor control signal to operate a motor that drives a servo valve to control the positive pressure applied to the subject's airway.
  • the apparatus output pressure is determined as a function of both detected pressure and flow. Further, the pressure must be output at a value sufficient to maintain a constant ratio of pressure to flow.
  • the phrenic efferent respiratory discharge serves as the apparatus command signal and is processed to produce a moving time average (MTA) and the subject's tracheal pressure serves as a negative feedback signal.
  • MTA moving time average
  • the Remmers et al. apparatus provides respiratory assistance only during inspiration.
  • the measured values are converted into electrical signals and the flow and pressure of the respiration gas are controlled during the inspiration and expiration portions of the respiration cycle via a valve arranged between a respiration gas source and the measuring device.
  • the method for regulating the flow and pressure output comprises (1) measuring the actual flow of respiration gas proximate the patient, (2) measuring the actual pressure of respiration gas proximate the patient, (3) calculating nominal values of flow and pressure from preselected fixed values and the actual values, (4) comparing the actual values measured for the flow and pressure with the nominal values, and (5) obtaining from the comparison a control signal for modulating the valve and thereby regulating the flow and pressure of the respiration gas.
  • the Ernst et al. system although capable of delivering a base pressure equivalent to a patient's required end expiratory pressure, is nevertheless unable to deliver any pressure less than the base pressure. Consequently, the Ernst et al. apparatus requires the patient to perform more breathing work than is necessary to satisfy his respiratory needs, especially in the expiratory phase of a respiration cycle, thereby deleteriously affecting the patient's comfort and likelihood of continued compliance with the treatment.
  • CHF congestive heart failure
  • the pressure in the chest cavity is also impacted by respiration effort. With inspiration, the pressure in the chest is reduced (negative relative to resting pressure) due to inspiratory effort. This forces the heart to pump harder to move blood into the body. With expiration, the pressure in the chest is slightly increased (positive relative to resting pressure) due to the elastic properties of the chest. This allows the heart to decrease its efforts to pump blood. While conventional CPAP can help the heart rest, it has negative aspects for the patient such as increased work of exhalation and discomfort from the pressure.
  • This object is achieved by providing an apparatus for delivering pressurized breathing gas to an airway of a patient.
  • the apparatus which is referred to below as a “proportional positive airway pressure” or “PPAP” apparatus, includes a gas flow generator, a patient interface that couples the gas flow generator to the patient's airway, a sensor that detects a fluid characteristic associated with a flow of gas within the patient interface, a pressure controller that regulates the pressure of breathing gas provided to the patient, and a control unit that controls the pressure controller.
  • PPAP proportional positive airway pressure
  • control unit controls the pressure controller so that the breathing gas is delivered using the gas flow generator and the patient interface.
  • the system determines that the patient is experiencing an apnea and, in response, performs a pressure change maneuver. This maneuver includes increasing a pressure of the flow of gas for a period of time, and decreasing the pressure of the flow of gas after the pressure increase.
  • the system then monitors the change in flow rate for the flow of gas resulting from the pressure change maneuver, if any, and determines whether the airway of the patient is open or closed based on the monitored change in the flow rate.
  • FIG. 1 is a functional block diagram of an apparatus according to the instant invention
  • FIG. 2 is a functional block diagram of a further embodiment of an apparatus according to the instant invention.
  • FIGS. 3A and 3B are flow and pressure diagrams, respectively, graphically representing the general manner in which an apparatus according to the instant invention outputs pressurized breathing gas in a proportional relation to the patient flow in both the inspiratory and expiratory phases of a single respiratory cycle;
  • FIGS. 4A and 4B are flow and pressure diagrams, respectively, similar to FIGS. 3A and 3B , exemplifying a number of apparatus output pressure curves that are achieved through selective adjustment of inspiratory and expiratory gain setting controls of the proportional positive airway pressure circuitry of the instant invention;
  • FIGS. 5A and 5B are flow and pressure diagrams, respectively, similar to FIGS. 3A and 3B , contrasting a pressure output curve typical of an apparatus according to the instant invention with pressure output curves of a conventional respiratory assistance apparatus;
  • FIGS. 6A and 6B are flow and pressure diagrams, respectively, similar to FIGS. 3A and 3B , depicting alternative pressure profiles that are employed at the beginning of an inspiratory phase of respiration to facilitate the onset of inspiration;
  • FIGS. 7A and 7B are flow and pressure diagrams, respectively, similar to FIGS. 3A and 3B , illustrating a resultant apparatus pressure output curve according to a further embodiment of the present invention
  • FIGS. 8A and 8B are flow and pressure diagrams, respectively, similar to FIGS. 3A and 3B , showing a resultant apparatus pressure output curve achieved by combing a conventional bi-level positive airway pressure therapy with the proportional positive airway pressure therapy according to the instant invention;
  • FIGS. 9A and 9B are flow and pressure diagrams, respectively, similar to FIGS. 3A and 3B , reflecting a further resultant apparatus pressure output curve achieved by combining a conventional bi-level positive airway pressure therapy with proportional positive airway pressure therapy according to the instant invention;
  • FIG. 10 is a functional block diagram of a further embodiment of an apparatus according to the instant invention.
  • FIGS. 11A and 11B are flow and pressure diagrams, respectively, similar to FIGS. 7A and 7B , illustrating a resultant apparatus pressure output curve according to a further embodiment of the present invention that utilizes a simplified pressure profile generating technique;
  • FIG. 12 is a pressure diagram illustrating the occurrence of oscillations in the pressure provided to the patient during exhalation
  • FIG. 13 is a pressure diagram illustrating a first technique for reducing the oscillations illustrated in FIG. 12 ;
  • FIG. 14 is a pressure diagram illustrating a second technique for reducing the oscillations illustrated in FIG. 12 ;
  • FIG. 15 is a pressure and flow diagram illustrating a further technique for handling pressure oscillations during the expiratory phase of the breathing cycle.
  • FIG. 1 a proportional positive airway pressure apparatus according to a presently preferred embodiment of the instant invention and shown in the form of a functional block diagram.
  • Apparatus 10 is operable according to a novel process to deliver breathing gas, such as air, oxygen or a mixture thereof, at relatively higher and lower pressures (i.e., generally equal to or above ambient atmospheric pressure) to a patient 12 in proportion to the patient's respiratory flow for treatment of OSAS, snoring, CHF, COPD and other respiratory or cardio-respiratory disorders.
  • breathing gas such as air, oxygen or a mixture thereof
  • Apparatus 10 includes a gas flow generator 14 , such as a conventional CPAP or bi-level PAP blower, i.e., a centrifugal blower, that receives breathing gas from any suitable source, e.g., a pressurized bottle 16 of oxygen or air, the ambient atmosphere, or a combination thereof.
  • the gas flow from flow generator 14 is passed via a delivery conduit 18 to a breathing appliance or patient interface 20 of any suitable known construction that is worn by patient 12 .
  • the conduit 18 is a large bore flexible tube and the patient interface 20 is either a nasal mask or a full face mask, as shown.
  • the phrase “patient interface” can encompass more that the interface worn by the patient.
  • the patient interface can include delivery conduit 18 and any other structures that connect the source of pressurized breathing gas to the patient.
  • the apparatus also includes a sensor, such as a flow transducer 22 or similar flow sensing element, situated within or near the breathing circuit, i.e., the patient interface 20 , conduit 18 or gas flow generator 14 .
  • Flow transducer 22 may be any suitable gas flow meter, such as, for example, a bidirectional dynamic mass flow sensor.
  • the flow transducer is a pressure responsive sensor for detecting the magnitude of the pressure gradients between the inlet of the patient's airway and his lungs.
  • flow and respiratory pressure gradient are highly correlated.
  • the flow sensor need not be coupled directly to conduit 18 .
  • the present invention contemplates the use of any sensor or a plurality of sensors that can measure the flow of breathing gas in the conduit.
  • flow in the system can be measured at the patient interface device or can be measured or estimated from the motor or piston speed, power, current, torque, or feedback control used to provide the elevated pressure by flow generator 14 .
  • the sensor need not be a direct flow measurement, but can be determined indirectly from measurements associated with the flow generator.
  • the present invention contemplates any conventional technique for measuring the flow of gas delivered to the patient as flow transducer 22 .
  • the flow transducer 22 is interposed in line with conduit means 18 , most preferably downstream of a pressure controller 24 .
  • the flow transducer generates output signals that are provided, as indicated by reference numeral 26 , to PPAP circuitry 28 described in greater detail hereinafter.
  • the output signals include first flow rate signals indicative of inspiration by the patient and second flow rate signals indicative of the patient's expiration.
  • the signals are continuously transmitted and correspond to the instantaneous flow rate of breathing gas within conduit means 18 .
  • the output from flow transducer 22 is also desirably provided, as indicated by reference numeral 30 , to an optional leak detecting system 32 .
  • a suitable leak detector for present purposes is that disclosed in U.S. Pat. No. 5,148,802, the disclosure of which is incorporated herein by reference.
  • other techniques for substantially instantaneously calculating system leakage including both known leakage, such as that discharged through a mask exhaust port 34 , and unknown leakage, such as that at various conduit couplings or at the patient contact site of the patient interface 20 , are acceptable.
  • the patient flow must be estimated taking into account the aforesaid known and unknown system leaks.
  • the output signal from the leak detecting system 32 is provide, as at 36 , to PPAP circuitry 28 .
  • the PPAP circuitry logic continuously compares the output from flow transducer 22 with that from leak detecting system 32 to discriminate that portion of system flow associated with the patient's respiration from that caused by system leakage.
  • PPAP circuitry 28 more precisely controls the output of the pressure controller 24 as a function of patient respiratory flow, rather than overall system flow.
  • patient interface 20 commonly includes, as mentioned above, a suitable exhaust system, schematically indicated at 34 , to exhaust breathing gases during expiration.
  • Exhaust system 34 preferably is a continuously open port that imposes a suitable flow resistance upon exhaust gas flow to permit pressure controller 24 , located in line with conduit 18 between flow generator 14 and patient interface 20 , to control the pressure of air flow within the conduit and thus within the airway of the patient.
  • exhaust port 34 may be of sufficient cross-sectional flow area to sustain a continuous exhaust flow of approximately 15 liters per minute at a system pressure of 10 cm H 2 O.
  • the flow via exhaust port 34 is one component, and, typically, the major component of the overall system leakage, which is an important parameter of system operation.
  • a non-rebreathing valve may be substituted for the continuously open port.
  • Pressure controller 24 controls the pressure of breathing gas within conduit 18 and thus within the airway of the patient.
  • Pressure controller 24 is located preferably, although not necessarily, downstream of flow generator 14 and may take the form of an adjustable, electronically-controlled valve.
  • other method of pressure control are contemplated by the present invention, such as controlling the operation of the pressure generator, either alone or in combination with a pressure control valve.
  • the pressure generator is a blower, which includes an impeller mounted in a housing and rotated by a motor.
  • the pressure controller is a control system that controls the operating speed of the motor in the blower without the need for a dedicated flow control valve.
  • Apparatus 10 also desirably includes a safety circuit, preferably comprising an adjustable maximum pressure setting control 38 and an adjustable minimum pressure setting control 40 operatively connected to pressure controller 24 .
  • the safety circuit allows the manufacturer, the patient or his overseeing health care professional to selectively establish minimum and maximum system output pressures below and above which the system will not dispense pressurized gas.
  • the minimum pressure will, of course, be at least zero and, preferably, a threshold pressure sufficient to maintain pharyngeal patency during expiration.
  • the maximum pressure on the other hand, will be a pressure somewhat less than that which would result in over-inflation and perhaps rupture of the patient's lungs.
  • the safety circuit functions differently than the pressure controls which determine, for instance, the CPAP prescription pressure or the IPAP and EPAP prescription pressures used in bi-level PAP therapy. That is, instead of establishing lower and upper prescription pressures to be administered during normal usage of the apparatus (subject to the influence of the PPAP circuitry 28 ), the maximum and minimum pressure setting controls 38 and 40 set absolute minimum and maximum fail-safe output pressure limits which are not to be exceeded. Thus, the danger of potential physical harm to the patient in the even of malfunction of other system components, e.g., the prescription pressure controls, is effectively eliminated.
  • PPAP circuitry 28 is subject to the influence of additional essential controls, including a base pressure control 42 , an inspiratory gain setting control 44 , and an expiratory gain setting control 46 .
  • the base pressure control 42 establishes a base pressure (Pbase), usually greater than or equal to zero and conceptually equal to the EPAP level in bi-level therapy, sufficient to maintain airway patency at the beginning and end of exhalation.
  • the inspiratory gain setting control 44 permits selection of a resistive gain (Gain Insp ) to be applied to the detected inspiratory flow.
  • the expiratory gain setting control 46 enables selection of a resistive gain (Gain Insp ) to be applied to the detected expiratory flow.
  • PPAP therapy and the PPAP apparatus 10 constitute a novel system providing pressure to a patient via nasal, nasal/oral, oral, or trachea interface to treat OSAS, COPD and other breathing disorders.
  • the pressure delivered to the patient is a function of the patient flow rate. The function can be described as follows:
  • “Pdelivered” is the pressure delivered to the patient interface
  • “Pbase” is the base line pressure (greater than or equal to zero and conceptually equal to EPAP)
  • Flow is the estimated patient flow rate determined by the flow transducer
  • “Gain” is the constant used to augment pressure based on the flow rate. The gain constant can further be refined to allow one constant for inspiration (positive flow) and a different constant for exhalation (negative flow).
  • FIGS. 3A and 3B represent flow and pressure diagrams, respectively, graphically depicting the manner in which apparatus 10 outputs pressurized breathing gas in proportional relation to patient flow, as detected by flow transducer 22 , in both the inspiratory and expiratory phases of a respiratory cycle.
  • the pressure curve of FIG. 3B reflects a situation where the same gain is chosen for both inspiratory and expiratory flow.
  • essentially the same pressure curve may be generated by the apparatus disclosed in the aforementioned essay entitled “An Apparatus for Altering the Mechanical Load of the Respiratory System,” by Younes, et al. which may use a single resistive gain applicable to both inspiration and expiration.
  • the pressure output of the PPAP apparatus 10 is more accurately described according to the following functions, which functions can be encoded into the PPAP circuitry 28 .
  • Gain Insp is the constant used during inspiration (positive flow) to boost pressure based on the flow rate
  • Gain Exp is the constant used during exhalation (negative flow) to reduce pressure based on the flow rate
  • the gain typically selected has a range of about 0 to 10 cm H 2 O/liter/second for inspiration.
  • the gain chosen for exhalation is normally lower than the inspiratory gain, e.g., values in the range of 0 to 4 cm H 2 O/liter/second, although higher gain values may be chosen for inspiration and/or expiration, if such is desired or necessary.
  • FIGS. 4A and 4B perhaps most clearly exemplify the effect that the selection of different gains for both the inspiratory and expiratory phases of a respiratory cycle has upon the pressure output curve.
  • Gain Insp(a) , Gain Insp(b) , Gain Insp(c) and Gain Insp(d) represent, in descending order, several of an infinite range of gain values that may be applied during inspiration.
  • Gain Exp(e) , Gain Exp(f) , Gain Exp(g) and Gain Exp(h) indicate increasing expiratory gain values.
  • any number of wave forms can be generated. For example, a high setting may be established for Gain Insp and a low setting for Gain Exp , or vice versa, or the gain settings for inspiratory flow and expiratory flow may be the same.
  • PPAP therapy seeks to provide only the pressure that is necessary to prevent airway collapse at any given moment during the breathing cycle. This will generally result in supplying, at appropriate times, maximum pressure only when peak negative airway inspiratory pressures are detected and minimum pressure only when peak positive airway exhalation pressures are detected. At all other times during the breathing cycle, the PPAP apparatus delivers air at a variable pressure responsive to the patient's respiratory efforts in a range between the maximum and minimum pressures. As mentioned above, PPAP therapy also involves the administration of a base pressure of zero or greater to which the product of a selected gain times instantaneous flow (inspiratory and expiratory) is continuously added to produce the instantaneous output pressure of the PPAP apparatus.
  • the base pressure will be the pressure necessary to overcome any mechanical collapsing forces that result from the structure of the airway tissues, muscle tone, and body position. In other words, the base pressure is generally equivalent to the expiratory positive airway pressure or “EPAP” typically used in bi-level PPAP therapy.
  • FIG. 5B illustrates the pressure output curve generated by the PPAP apparatus 10 vis-a-vis conventional CPAP and bi-level PAP apparatus over a single respiratory cycle. So long as the appropriate inspiratory and expiratory splint pressures are applied at point 48 (peak inspiratory flow), point 50 (beginning of exhalation) and point 52 (end of exhalation), less pressure may be provided at all other times during the breathing cycle than is normally supplied by conventional CPAP or bi-level PAP therapy. This reduced output pressure is represented by the “PPAP” curve of FIG. 5B .
  • the hatched areas of that figure reflect the difference in pressures provided by PPAP and the IPAP and EPAP phases of bi-level PAP during a typical respiratory cycle.
  • PPAP therapy thus represents a novel respiratory disorder treatment by which patient comfort (and, therefore, treatment compliance) exceed that offered by either CPAP or bi-level PAP therapy.
  • command signals 54 are the product of the influences of one or more of the outputs from flow transducer 22 , leak detection system 32 , base pressure control 42 , inspiratory gain setting control 44 , expiratory gain setting control and, in an alternative embodiment, a pressure profile control 56 discussed below.
  • a temporary pressure increase can be added at the start of inspiration to support to the airway until sufficient flow is generated to drive the PPAP process.
  • the present invention offers several viable approaches by means of which pressure can be added during the initial phase of inspiration to support the airway as inspiratory flow increases.
  • Temporary pressure increases may be effected using pressure profile control 56 in operative connection with PPAP circuitry 28 to select a desired elevated pressure waveform in the early stages of inspiration.
  • pressure profiles may be used as minimum values for the output pressure at the outset of inspiration, thereby giving rise to the following alternative equations for available output pressure during inspiration.
  • “Pinhalation” is the pressure delivered to the patient interface during inspiration
  • “Pbase” is the base line pressure (conceptually equal to EPAP)
  • “Flow” is the estimated patient flow
  • “Gain Insp ” is the constant used during inspiration (positive flow) to boost pressure based on the flow rate
  • “Pprofile” is a function that generates a pressure profile to support the airway at the start of inspiration.
  • Such pressure profile functions may be constant, e.g., a step profile as shown by the dotted line identified by numeral 58 in FIG. 6B , time based (for instance, a backwards ramp profile as shown by the dotted and dashed line identified by numeral 60 in FIG. 6B ), or any other functional shape.
  • pressure profiles can be used exclusively to control the output pressure for a predetermined initial segment of inspiration.
  • the following equations represent system output pressure during inspiration under such control conditions.
  • Pinhalation Pprofile from start of breath to X
  • “Pinhalation” is the pressure delivered to the patient interface during inspiration
  • “Pbase” is the base line pressure (conceptually equal to EPAP)
  • Flow is the estimated patient flow
  • “Gain Insp ” is the constant used during inspiration (positive flow) to boost pressure based on the flow rate
  • “Pprofile” is any function that generates a pressure profile to support the airway at the start of inspiration. Such functions could be constant, such as, for example, a step profile, or time based, such as a backwards ramp profile, or any other functional shape.
  • “X” is a preselected transition point determined by time, or analysis of the flow signal, such as curvature, percent drop from peak flow rate, integration, derivative, analysis of prior breaths or a combination of flow analysis and time.
  • the PPAP apparatus 10 also has the capacity to measure and store in a memory 62 ( FIG. 1 ) the following parameters: tidal volume, inspiratory time, expiratory time, peak pressure, peak flow, 0 2 saturation (as a voltage input from an external source), plural pressure (as a voltage input from an outside source), mask pressure, estimated leakage, and system parameters, e.g., Pbase, Auto Gain Insp , Gain Insp , Gain Esp , IPAP and EPAP. It is to be understood that this list is not exclusive; other parameters can be stored in memory 62 .
  • a further method by which the present system addresses the problem presented by the changing needs of the patient is to combine the beneficial features of PPAP with a more controlled therapy such as CPAP, as is shown in FIGS. 7A and 7B .
  • the CPAP pressure for this embodiment can be fixed for all time during the therapy session or it can vary over the course of the treatment session.
  • it is known to provide a patient with an auto-titrating CPAP pressure where the CPAP pressure is varied based on the monitored condition of the patient, the condition of the pressure support system, or both.
  • the present invention contemplates combining PPAP during exhalation with an auto-titrating CPAP pressure during inhalation, so that the CPAP pressure is determined using any conventional auto-titration technique, such as that taught by U.S. Pat. Nos. 5,203,343; 5,458,137 and 6,087,747 all to Axe et al. or U.S. Pat. No. 5,645,053 to Remmers et al.
  • patient comfort can be increased when using the PPAP-CPAP combination. It can happen when using conventional triggering techniques, that the trigger from inspiration to expiration is detected before the patient's flow reaches zero. In other words, the patient's expiratory effort begins, not at the zero flow point, but at a period of time slightly before that point. For example, at point “p” in FIG. 7A the pressure support system may consider the patient to be in the expiratory phase of the breathing cycle.
  • a further embodiment of the present invention contemplates calculating Pexhalation at the trigger from inspiration to expiration as follows:
  • FlowOffset corresponds to the last value of patient flow (if positive) during inspiration.
  • the FlowOffset value allows Pexhalation to be calculated at point “p” in FIG. 7A , but accounts for the fact that the flow is positive at this point by subtracting out an equal or greater amount of flow using the FlowOffset value. Pexhalation is calculated using the FlowOffset only if the Flow is positive. Otherwise, the FlowOffset can be removed or set to zero.
  • FlowOffset must be decreased during the expiratory phase to ensure that the offset reaches zero by the end of expiration, i.e., when the patient's flow increases back to zero, so that the pressure relief returns to zero at that time.
  • the decrease on FlowOffset can be done periodically or continuously throughout the expiratory phase.
  • FIGS. 8A and 8B demonstrate that PPAP can also be combined with bi-level PAP therapy in a number of ways to produce effective therapeutic pressure waveforms.
  • One application generally similar to the aforementioned PPAP-CPAP scenario, is to use PPAP to lower the pressure during exhalation.
  • the resulting equations for the delivery of composite PPAP-bi-level PAP pressure are as follows:
  • FIGS. 9A and 9B Another approach to merging PPAP with bi-level therapy is shown in FIGS. 9A and 9B where IPAP is applied to the patient for a first portion of the inspiratory cycle and PPAP is applied for the remainder of the breathing cycle.
  • Gain Insp is automatically calculated for each breath based on IPAP and the flow rate as follows:
  • Flow is the estimated flow rate
  • t 0 is the time at the start of breath
  • t 1 is the time when the estimated flow rate is a predetermined percentage of peak inspiratory flow rate
  • t 2 is the time at the start of exhalation
  • IPAP is a continuously applied inspiratory positive airway pressure
  • Pinhalation (t 0 to t 1 ) is the pressure delivered to the patent from t 0 to t 1
  • Pbase is a continuous base pressure
  • AutoGain Insp equals (IPAP ⁇ Pbase)/Flow at t 1
  • Pinhalation (t 1 to t 2 ) is the pressure delivered to the patient from t 1 to t 2
  • Gain Exp is the constant used during exhalation to reduce pressure delivered to the patient
  • Pexhalation is the pressure delivered to the patient during exhalation.
  • FIGS. 3A through 9B represent the apparatus output pressure and flow during the inspiratory and expiratory phases of a single respiratory cycle.
  • the PPAP and flow curves can, of course, be expected to vary somewhat from respiratory cycle to respiratory cycle depending on the patient's respiratory requirements, particularly under fully automated PPAP therapy described hereinafter. Furthermore, somewhat greater variations will likely occur between the respiratory cycles associated with different stages of an extended treatment session, especially during OSAS treatment.
  • FIG. 2 represents a further preferred embodiment of a PPAP apparatus pursuant to the present invention, designated herein by reference numeral 10 ′.
  • IPAP/EPAP bi-level PPAP circuitry 64
  • PPAP apparatus 10 ′ is identical in structure and function to PPAP apparatus 10 .
  • output 66 from flow transducer 22 is fed to bi-level PAP circuitry 64 .
  • Bi-level PAP circuitry 64 may assume any conventional form such as, for example, that described in U.S. Pat. Nos. 5,148,802; 5,433,193; and 5,632,269, the contents or which are incorporated herein by reference.
  • Output 68 from bi-level PPAP circuitry 64 is transmitted to the PPAP circuitry 28 .
  • Output 68 consists of an IPAP signal if the patient is inhaling and an EPAP signal in the event the patient is exhaling.
  • the logic of the PPAP circuitry 28 utilizes this input according to a preselected one any of the aforementioned combinations of PPAP-bi-level therapy to generate a desired pressure command signal 54 .
  • the pressure delivered to the patient is determined by the base pressure, the flow rate and the gain (and the pressure profile if used). For a given patient condition, these settings can be adjusted as necessary to stabilize the airway.
  • OSAS a patient's periodic and, to a lesser extent, instantaneous condition is variable with sleep state and body position.
  • settings that may work well in during one portion of a sleeping session may not work as well at a different time.
  • settings that support the airway at its most unstable state may cause pressures that are higher than necessary during more stable times.
  • settings that work well at one point in the session may be insufficient at another time.
  • the present invention proposes several methods to minimize the impact of the patient's changing needs on the optimization of PPAP therapy.
  • One such method is to automatically adjust the gain, pressure profile and baseline pressure to meet the patient's demands. This adjustment can be based on analysis of patient parameters related to flow, e.g., magnitude, shape, derivative, integral (volume), pressure, snoring, arterial oxygen saturation, exhaled C0 2 , airway diameter, or other parameters.
  • the system may adjust the Gain Insp to prevent partial airway obstruction (hypopnea).
  • the goal of such systems is to increase Gain Insp responsive to any of the following patient conditions:
  • the apparatus according to the invention may also maintain minimal Gain Insp in the absence of these conditions.
  • the present system may also adjust the base pressure (Pbase) to prevent complete collapse of the airway (apnea) or severe collapse (severe hypopnea).
  • Pbase base pressure
  • Apnea can be detected by analysis of the flow signal and/or by using reflected pressure waves, or a combination of pressure and flow to determine airway patency.
  • it may be important to determine if the apnea is caused by airway collapse or by a lack of respiratory drive. If an obstructive event is detected the base pressure can therefore be increased to open the airway.
  • a further capability of the present system is to maintain a minimum Pbase in the absence of these conditions.
  • the system may also adjust the pressure profile (Pprofile) to prevent apnea or hypopnea at the onset of inspiration.
  • Pprofile the pressure profile
  • the system may increase Pprofile in response to decreased inspiratory flow, decreased respiratory volume, flow waveform shape analysis that indicates increasing airway resistance, pressure or sound variations indicative of airway instability, drops in arterial oxygen saturation, decreases in airway diameter or a change in exhaled C0 2 .
  • the present invention also functions to maintain the minimum pressure profile in the absence of these conditions.
  • FIG. 10 reveals a presently preferred embodiment of a fully automated PPAP apparatus 10 ′′ constructed according to the present invention.
  • PPAP apparatus 10 ′′ additionally incorporates a microprocessor or central processing unit (CPU) 70 that preferably utilizes an output signal 72 from flow transducer 28 as a continuous feedback signal to enable the CPU to continuously adjust Pbase, Pprofile, Gain Insp , and Gain Exp as necessary.
  • the CPU may, however, be configured to effect its continuous system control functions responsive to any of the aforementioned patient parameters related or unrelated to respiratory flow.
  • Apparatus 10 also has the capability to detect hypopnea, as evidenced by decreases in peak flow and/or tidal volume for a given period of time, and the occurrence of apneas, as manifested by very little flow for a given period of time.
  • the CPU 70 may be programmed to make a comparison between a short term average of peak inspiratory flow rate or tidal volume (e.g., a 3 breath average) and a long term average of peak flow rate or tidal volume (e.g., greater than 20 breaths). If a decrease of greater than 25% is detected the system determines a hypopnea to be present. This determination is desirably made only if the leakage is well estimated and stable. Thus, large changes in leak or initiation of a leak recovery will cause data to be ignored.
  • the invention further includes a method for determining if the airway is open (central apnea) or obstructed (obstructive apnea) during an apnea.
  • the PPAP apparatus 10 ′′ controls are automatically adjusted as follows. In the event of a hypopnea, Gain Insp is increased by 2 cm/liter/second. In the event of an obstructive apnea, Pbase is increased by 1 cm H 2 O. The device will continue to increase Pbase as long as an obstructive apnea of significant duration is detected. The device will not increase Gain Insp again, if necessary, until 5 breaths have passed. If no hypopnea or apneas occur over a period of 30 breaths, Gain Insp is decreased by 1 cm/liter/second.
  • the apparatus may control the delivery of 0 2 while patient flow is greater than zero, if such desired or necessary.
  • CPAP or IPAP may be controlled using the same logic that controls Gain Insp in the above-described fully automated PPAP system.
  • Pbase may be controlled in a similar manner to that described in connection with fully automated PPAP.
  • the fully automated PPAP-CPAP or PPAP-bi-level PAP systems may also adjust Pprofile to prevent apnea or hypopnea at the start of inspiration. Such systems may therefore increase CPAP (or IPAP) or Pprofile in the face any of the following patient conditions:
  • PPAP therapy therefore, it is additionally possible to employ PPAP in response to expiratory flow to reduce pressure applied during expiration to less than the patient's PEEP level throughout all but the end of the expiratory phase in a manner similar to that described for lowering the pressure below Pbase during exhalation in the treatment of OSAS.
  • This lowering of applied pressure to less than PEEP during the expiratory phase diminishes breathing work and enhances patient comfort when compared to the constant expiratory phase pressure applied during EPAP.
  • PPAP can be adapted to any ventilation mode that uses PEEP.
  • Such applications may include pressure support with PEEP, PAV with PEEP or other applications of PEEP in respiratory assistance therapy.
  • the present invention contemplates providing different inspiratory gains or expiratory gains depending on the pressure support needs of the patient. See, e.g., FIG. 4B and the associated text.
  • a further embodiment of the invention contemplates allowing the patient to select the gain (inspiratory or expiratory) so that the user can try different gains to determine which gain provides the best pressure support therapy. It can be appreciated that this embodiment is best suited for allowing the patient to select the expiratory gain, such as when using the PPAP-CPAP combination, because it is commonly accepted that the inspiratory positive pressure, and, hence, the inspiratory gain, should be set by a physician and should not be altered by the patient.
  • the present invention contemplates having a user select a first expiratory gain setting and use the pressure support system at that gain.
  • the efficacy, comfort, or both of the pressure support system operating at the first gain can then be monitored using any conventional technique, such as by having the patient complete a questionnaire. See, for example, published PCT application publication no. WO00/18347, which teaches a technique for providing a pressure support system and an efficacy questionnaire.
  • the user selects a second expiratory gain different than the first.
  • the efficacy, comfort, or both of the pressure support system operating at the second gain can then be monitored and compared against the results garnered using the first gain. This process can be repeated using still other gains. In this manner, the optimal gain can be determined.
  • the present invention also contemplates allowing the user to adjust the base pressure to determine its optimum level using the above-described technique.
  • the present invention further contemplates that the above-described patient-feedback determination of the optical gain or base pressure can be performed automatically.
  • the pressure support system can be programmed to automatically provide different gains or base pressures during different therapy sessions. After each session the user can be prompted to take a survey to gauge the effectiveness, comfort, or both of that therapy session. After sufficient data is collected the system can then automatically select the gain or base pressure based on the survey results that is optimum for that patient.
  • the administration of oxygen in phase with inspiration may also easily be included with PPAP therapy for the treatment of COPD patients requiring supplemental oxygen.
  • the pressure of the gas being provided to the patient can be controlled so as to vary over time.
  • the pressure provided to the patient increases from a first minimum pressure to a desired therapy pressure over a period of time.
  • This ramp increase in pressure provides the patient with time to fall asleep under relatively low pressure that is increased to the therapy pressure over time. Thereafter, the pressure increases so that the therapy pressure is being applied after the patient is asleep.
  • a reverse process can be performed in the morning, with the pressure being decreased from the therapy pressure shortly before the patient intends to wake up.
  • Ramp control 120 in FIG. 10 schematically illustrates a manually actuated controller that provides commands to PPAP circuitry 28 to cause the pressure to be provided according to a ramp cycle.
  • the ramp control may be adjusted according to the output of CPU 70 .
  • Ramp control 120 can be used to set the parameters associated with the ramp function, such as the ramp period, ramp start time, ramp stop time, and ramp shape.
  • an alarm 122 is coupled to PPAP circuitry 28 and/or CPU 70 .
  • Alarm 122 can be controlled so as to be actuated as a result of a variety of circumstances. However, in a preferred embodiment of the invention, alarm 122 is actuated responsive to an automatically determined gain falling outside a predetermined range of values.
  • the present invention also contemplates limiting a value for an automatically determined gain, such as AutoGain Insp discussed above, to prevent the automatically determined gain from exceeding predetermined limits, for example, from exceeding limits that may result in an excessively high pressure being provided to the patient.
  • the limits on the amount that the gain can themselves be altered so that these limits vary over a predetermined period of time.
  • the amount of change that may take place in the automatically determined gain over a predetermined period of time can also be controlled, thereby preventing the automatically determined gain from changing by more than a predetermined amount over the predetermined period of time.
  • the present invention reduces mean pressure and work of exhalation while still providing the same level of rest to the heart.
  • a positive base pressure substantially equivalent to a pressure needed to reduce cardiac preload and afterload (preferably in the range of 5-10 cm H 2 O)
  • the present invention helps the heart reduce its efforts. With additional positive pressure during inspiration in proportion to respiratory effort, one can overcome the effect of negative pressure being produced during inspiration.
  • PPAP is particularly appropriate in CHF patients in that the typical CHF patient has normal lung compliance. In these patients, much of the respiratory loading can be inferred from the flow signal.
  • By reducing the pressure below the base pressure during exhalation one can reduce the work of exhalation without, reducing the benefit to the heart. The net effect will be the same benefit to the heart with reduced work of breathing and lower mean pressure.
  • PPAP therapy for the treatment of CHF delivers only the minimum amount of pressure needed to reduce cardiac preload and afterload. This will result in supplying a base pressure to the exterior of the heart equivalent to the pressure needed to reduce cardiac preload and afterload in the absence of respiratory loading and a varying pressure which is needed to overcome the impact of respiratory loading on cardiac preload and afterload while minimizing the work of breathing.
  • the positive pressure will reduce the enlarged heart of a CHF patient to a size closer to normal. This return to normal size, allows the muscles of the heart to work more effectively.
  • the positive pressure in the chest cavity reduces the amount of pressure the heart must overcome to pump blood to the rest of the body.
  • the heart and chest cavity are at the same pressure. Typically this pressure fluctuates about ambient pressure due to the impact of respiratory loading.
  • the circulatory system has a working pressure that varies as the heart pumps but averages 100 mm HG in normal-tensive patients.
  • the heart must supply the power to force blood from the chest cavity into the pressurized circulatory system. Increasing the pressure in the chest cavity reduces the amount of pressure the heart must over come to pump blood.
  • a pressure in the chest cavity of 10 cm H 2 O or approximately 10 mm Hg will reduce the load on the heart by 10 mm Hg/100 mm Hg or roughly 10%.
  • PPAP is able to offset the increase in chest cavity pressure and maintain a relatively constant pressure in the chest.
  • variable portion of PPAP allows a lower baseline to be set relative to using a constant pressure with the same benefits to the heart. This lower baseline and reduced pressure during exhalation also reduces the work of breathing and increases patient comfort.
  • Providing a version of PPAP on existing CPAP devices enhances the patient comfort and, hence, compliance without the significant financial and other burdens appurtenant to manufacturing and introducing a new CPAP device that includes a PPAP mode.
  • Providing a PPAP therapy on a CPAP device can be accomplished in a variety of ways, such as that discussed above with respect to FIGS. 7A and 7B .
  • a version of PPAP can be implemented on a CPAP system in a more cost effective manner if the reactive component used to generate the reduced pressure curve during exhalation in FIG. 7 is replaced with a defined reduced pressure profile.
  • This pressure profile replaces the constant CPAP pressure otherwise applied by the CPAP device during the expiratory phase of the patient's breathing cycle.
  • the defined pressure profile has a shape that generally corresponds to a patient's normal flow.
  • FIGS. 11A and 11B are flow and pressure diagrams similar to FIGS. 7A and 7B illustrating a resultant apparatus pressure output curve according to a further embodiment of the present invention that utilizes a simplified pressure profile generating technique.
  • Flow signal 80 in FIG. 11A illustrates the patient's inspiratory phase 82 and expiratory phase 84 .
  • a continuous CPAP pressure 86 is delivered during the inspiratory phase 82 .
  • the pressure support device is controlled to deliver a reduced pressure following a predetermined pressure profile 88 .
  • the resulting equations for pressure delivered under the combined CPAP and PPAP are as follows:
  • the predetermined pressure profile which is used to reduce the CPAP pressure, has a magnitude M, which is typically selected by a respiratory therapist in a range of 0-4 cmH 2 O, and a duration D that, unlike the pressure curve in FIG. 7B , is not directly determined base on the patient's instantaneous flow or volume.
  • the magnitude M represents the drop in pressure from the constant CPAP value.
  • the duration D value is preferably a fraction of an average expiration period of the patient.
  • FIG. 11B illustrates three predetermined pressure profiles P 1 , P 2 and P 3 , having magnitudes M 1 , M 2 and M 3 and durations D 1 , D 2 and D 3 , respectively.
  • the pressure profiles are selected so that the pressure provided to the patient during exhalation roughly correspond to the contour generated from flow or volume based PPAP, as shown, for example, in FIGS. 3A and 3B .
  • the pressure drops off quickly at the start of expiration then rises slowly toward the baseline CPAP pressure.
  • this embodiment for a CPAP/PPAP device does not control the flow and/or pressure provided to the patient based on the flow or pressure signal from the patient, as is the case with the PPAP devices and techniques discussed above, but instead, merely detects the start or expiration and/or inspiration, the sensor required by this embodiment need not be as accurate as in the previous embodiments.
  • a thermister or thermocouple could replace the costly pneumotach flow meter to determine the inspiratory and expiratory state.
  • the pressure profile provided to the patient during the expiratory phase can be generated using motor speed control, thereby avoiding the use of a pressure control valve.
  • oscillations 90 occur in the pressure waveform 92 applied to the patient during portions of the patient's expiratory phase 94 . These oscillations typically occur after the initial pressure drop following the onset of the expiratory phase and are believed to be generated as a result of the interaction of the patient's flow and the resulting pressure decrease.
  • FIG. 13 illustrates a pressure profile 92 ′ similar to profile 92 illustrated in FIG. 12 , except that the oscillations occurring during the expiratory phase have been removed using the above described technique. For example, at point 96 , which is after the maximum reduction in pressure at point 95 , the pressure begins to decrease from the immediately previous pressure due to a pressure oscillation.
  • the above oscillation prevention technique prevents this decrease by substituting the current pressure, i.e., the pressure at point 96 at all points thereafter where the calculated pressure, i.e., Pbase+Gain Exp *Flow, is less than the current pressure, thereby creating a plateau section 98 that corresponds to the pressure at point 96 , i.e., the current pressure, until a point 100 where the calculated pressure becomes greater than the current pressure. It should be noted that for purposes of this invention Flow is considered to be negative during the expiratory phase.
  • the device By ensuring that the pressure provided to the patient is always the greater of the current pressure and the calculated pressure, the pressure received by the patient during expiration does not oscillate. If the pressure to be provided to the patient begins to decrease below the current pressure, the device will not use the calculated pressure, but will continue to provide the patient with the current pressure, thereby preventing a pressure decrease below the current pressure.
  • Pbase can be a CPAP or IPAP pressure, as noted above.
  • the pressure oscillations are avoided by using an entirely different calculation for determining the pressure to be provided to the patient during the expiratory phase.
  • the calculation of the pressure to be provided to the patient is based on the volume of gas still contained in the lungs, referred to as the volume to be exhaled.
  • the volume to be exhaled corresponds to a difference between a current volume of gas in the patient and a volume of gas in the patient at rest.
  • the volume of gas currently in the lungs can be readily estimated from the flow signal.
  • the volume of gas in the patient at rest is determined using conventional techniques, and can be updated on a periodic base to ensure the accuracy of the calculation.
  • the pressure output by the PPAP device at least during a portion of the expiratory phase is described by the following function, which can be encoded into the PPAP circuitry:
  • “Pbase” is the base line pressure (greater than or equal to zero and conceptually equal to EPAP); “Volume to be exhaled ” is the difference between the current volume of gas in the patient less the volume of gas in the patient at rest; and “Gain Exp ” is the constant used during expiration (negative flow) to reduce pressure.
  • FIG. 14 illustrates a pressure curve 102 generated using the above equation to determine the pressure to be provided to the patient. It can be appreciated from FIG. 14 that pressure curve 102 accomplishes the functions of lowering the pressure during expiration and returning the pressure to the baseline at the end of the expiratory phase, preventing airway collapse.
  • volume of gas to be exhaled (Volume to be exhaled ) is relatively large at the onset of the expiratory phase, the pressure drop at the beginning of exhalation can be quite large. It is preferable to smooth the large drop at the onset of the expiratory phase by including a dampening factor in the calculation of the pressure to be provided to the patient.
  • t is a current time following the start of the expiratory phase
  • X is a predetermined transition point after the start of the expiratory phase determined by time, or analysis of the flow signal, such as curvature, percent drop from peak flow rate, integration, derivative, analysis of prior breaths or a combination of flow analysis and time.
  • the value of X is chosen so that the pressure provided to the patient during the initial period from t 0 to X is calculated taking into consideration the dampening factor t/X, thereby reducing the pressure drop at the onset of exhalation. Thereafter, the dampening factor is not taken into consideration and the exhalation pressure to be applied to the patient is calculated according to the second of the above two equations.
  • this embodiment of the present invention provides a smooth pressure curve throughout the expiratory phase while ensuring that the initial pressure drop at the start of the exhalation is within expectable parameters.
  • the pressure to be delivered to the patient (Pinhalation, Pexhalation) determined using the above-described techniques, is substantially continuously determined during the patient's breathing cycle.
  • the system is continuously calculating a new setpoint pressure to be delivered to the patient and controlling the pressure support system via the pressure controller to reach that setpoint pressure.
  • the setpoint pressures (Pinhalation, Pexhalation) determined using the above-described techniques are filtered using a low pass filter. This is done to smooth the transition from one calculated setpoint pressure to the next.
  • the low pass filter has a 50 msec time constant.
  • the rate of change for the setpoint pressure delivered to the patient is monitored and controlled to prevent sharp changes in the delivered pressure.
  • the limits on rate of change of the setpoint are limited to keep changes in the pressure to be delivered to the patient more comfortable for the patient. Rapid changes in the setpoint pressure may impact the patient's natural waveform. By limiting this impact, the result is a more comfortable therapy, especially in the PPAP-CPAP combination.
  • increasing the pressure to be delivered to the patient too quickly may cause the undesirable effect of an apparent early transition from expiration to inspiration.
  • the present invention contemplates controlling the rise rate, i.e., any increase in pressure, and/or the fall rate, i.e., any decrease in pressure, so that the rise rate and/or the fall rate is held within set limits.
  • the present invention contemplates that increases in the setpoint pressure to be delivered to the patient be made slower at the end of expiration.
  • the rise rate is more limited at the end of the expiratory phase than the rate at which fall rate is limited at the start of the expiratory phase.
  • the rate of change is controlled as follows. For positive changes in pressure, if the current calculated setpoint pressure is greater than the previous calculated setpoint pressure plus a rise rate limit, the current setpoint pressure is set to the previous setpoint pressure plus the rise rate limit, otherwise the current calculated pressure is used as the setpoint pressure. For negative changes in pressure, if the current calculated setpoint pressure is less than the previous setpoint pressure plus a fall rate limit, the current pressure to be delivered to the patient is set to the previous setpoint pressure plus the fall rate limit. Otherwise, the calculated setpoint pressure is used.
  • This feature of the present invention can be applied to the calculated Pinhalation setpoint pressure or the calculated Pexhalation setpoint pressure to ensure that pressure changes during either or both phase of the breathing cycle do not occur too sharply.
  • the setpoint pressure (Pinhalation or Pexhalation) need not be calculated continuously.
  • the setpoint pressure can be calculated using the above-described PPAP techniques during different stages of the respiratory cycle. In which case, filtering other rate of change control techniques can be used to smooth the transition from one setpoint pressure to the next.

Abstract

A system including methods and apparatus for treatment of a medical disorder such as obstructive sleep apnea or congestive heart failure. The system includes a gas flow generator and a patient interface. The system delivers a flow of gas to the patient using the gas flow generator and the patient interface. The system determines that the patient is experiencing an apnea and, in response, performs a pressure change maneuver. This maneuver includes increasing a pressure of the flow of gas for a period of time, and decreasing the pressure of the flow of gas after the pressure increase. The system then monitors the change in flow rate for the flow of gas resulting from the pressure change maneuver, if any, and determines whether the airway of the patient is open or closed based on the monitored change in the flow rate.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is continuation and claims priority under 35 U.S.C. §120 from U.S. patent application Ser. No. 11/926,867, filed Oct. 29, 2007, which claims priority under 35 U.S.C. §120 from U.S. patent application Ser. No. 11/182,387, filed Jul. 15, 2005, now U.S. Pat. No. 7,296,573, which is a continuation and claims priority under 35 U.S.C. §120 from U.S. patent application Ser. No. 10/304,590, filed Nov. 26, 2002, now U.S. Pat. No. 6,932,084, which is a continuation-in-part and claims priority under 35 U.S.C. §120 from of U.S. patent application Ser. No. 09/610,733 filed Jul. 6, 2000, now U.S. Pat. No. 6,609,517, which is a continuation and claims priority under 35 U.S.C. §120 from U.S. patent application Ser. No. 09/041,195 filed Mar. 12, 1998, now U.S. Pat. No. 6,105,575, which is a continuation-in-part and claims priority under 35 U.S.C. §120 from U.S. patent application Ser. No. 08/679,898 filed Jul. 15, 1996, now U.S. Pat. No. 5,749,615, which is a continuation-in-part and claims priority under 35 U.S.C. §120 from U.S. patent application Ser. No. 08/253,496 filed Jun. 3, 1994, now U.S. Pat. No. 5,535,738.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates generally to methods and apparatus for treating breathing and/or cardiac disorders and, more particularly, to methods and apparatus for providing a pressure to an airway of a patient during at least a portion of the breathing cycle to treat obstructive sleep apnea syndrome, chronic obstructive pulmonary disease, congestive heart failure, and other respiratory and/or breathing disorders.
  • 2. Description of the Related Art
  • During obstructive sleep apnea syndrome (OSAS), the airway is prone to narrowing and/or collapse while the patient sleeps. Continuous positive airway pressure (CPAP) therapy seeks to avoid this narrowing by supplying pressure to splint the airway open. With CPAP, this splinting pressure is constant and is optimized during a sleep study to be sufficient in magnitude to prevent narrowing of the airway. Providing a constant splinting pressure, i.e., CPAP, is a simple solution to the problem posed by the collapsing airway. However, this approach exposes the patient to pressures that are higher than the pressures needed to support the airway for most of the breathing cycle.
  • During inspiration, the pressure created within the lungs is lower than the pressure at the nose. This pressure difference drives the flow of air into the lungs. This pressure difference creates a pressure gradient in the airway connecting the lungs with the nose. That is to say, the nose is typically at ambient pressure while the lungs and airway of the patient are at sub-ambient or negative pressures. This negative pressure acts upon the airway and contributes to its collapse. CPAP levels are typically set to raise the pressure level in the entire respiratory system to the level required to both eliminate the sub-ambient pressures generated by inspiration and overcome any mechanical collapsing forces that result from the structure of the airway tissues, muscle tone, and body position. The inspiratory pressures, i.e., inspiratory positive airway pressure or “IPAP,” in bi-level positive airway pressure systems are set in a similar manner.
  • During exhalation, a positive pressure gradient exists between the interior of the lungs and the exterior of the body. This positive pressure gradient helps to support the airway during exhalation. At the end of exhalation, the pressure gradient is essentially zero; flow is likewise zero and the airway is unaffected by respiratory efforts. Any collapse of the airway at the end of exhalation is purely a function of the structure of the airway tissues, muscle tone, and body position. Bi-level devices seek to supply the expiratory pressure required to support the airway at the end of exhalation.
  • It should be noted that over the course of a breathing cycle, the pressure gradients between the lungs and the exterior of the body are not constant. The inspiratory pressure gradient falls from zero at the start of inspiration to a peak negative value and then rises back to zero at the end of inspiration. The expiratory pressure gradient rises from zero at the start of exhalation to a peak value and then falls back to zero as exhalation ends. Because the pressure gradient varies over the breathing cycle, the pressure necessary to overcome airway collapse should ideally vary over the breathing cycle.
  • Traditional CPAP therapy ignores these variations in pressure requirements and provides therapy at one pressure level. Conventional CPAP is rather crude and offers far from optimal therapy since the CPAP pressure is based solely on a worst-case treatment parameter, i.e., the peak pressure requirements during inspiration.
  • Representing an advancement over conventional CPAP, bi-level positive airway pressure (bi-level PAP) therapies seek to take advantage of the different pressure requirements to lower the pressure during exhalation. Nevertheless, bi-level therapies also fail to afford optimal treatment because the inspiratory positive airway pressure (IPAP) of bi-level PAP is again based on the patient's peak needs encountered during inspiration and remains constant over the entire inspiratory phase respiration. Also, during bi-level treatment, the expiratory position airway pressure (EPAP) remains constant and is related solely to the support needs at the end of exhalation.
  • In addition to OSAS, positive airway pressure therapy, such as bi-level PAP therapy, has been applied in the treatment of other breathing disorders, such as chronic obstructive pulmonary disorder (COPD). One of the problems with this mode of treatment, however, is that the patient has difficulty stopping inspiratory flow. This phenomenon arises due to the disparity between applied IPAP and the pressure needed to overcome the patient's respiratory resistance at the end of inspiration. As the former pressure typically exceeds the latter, the “surplus” IPAP at the end of inspiration leads to uncomfortable and potentially harmful hyperinflation of the patient lungs.
  • Conversely, in order to begin inspiratory flow, a COPD patient must reduce the pressure inside his lungs to a pressure that is less than the ambient pressure at the inlet of his respiratory system. Due to the condition commonly known as “Auto-PEEP,” the pressure in the patient's lungs is typically above ambient pressure at the end of exhalation. The patient's breathing muscles thus must perform additional work to expand the lungs and thereby reduce lung pressure below ambient before flow into the lungs can occur. Auto-PEEP is typically treated with a form of resistive counter pressure known as PEEP (positive end expiratory pressure). PEEP is set at a level just below the patient's Auto-PEEP level, thereby reducing the amount of breathing work required to initiate inspiratory flow.
  • With conventional treatments, such as pressure support, CPAP or bi-level therapy, PEEP is achieved by applying the same pressure over the entire phase of expiration, e.g., the EPAP phase of bi-level PAP therapy. It should be noted that EPAP is not synonymous with PEEP. EPAP indicates a constant pressure delivered to the patient throughout exhalation, while PEEP indicates positive end expiratory pressure. By definition, the PEEP pressure is only required at the end of exhalation. As such, the administration of EPAP throughout the expiratory cycle to assure that satisfactory PEEP is maintained undesirably contributes to the breathing work that a patient must perform during exhalation.
  • In addition to CPAP and bi-level PAP, other systems have been proposed for clinical research and/or therapeutic application, including treatment of OSAS, COPD and other breathing disorders, that offer an assortment of methods and apparatus by means of which a subject's respiratory efforts may be induced, superseded, assisted and/or resisted. Some of these systems perform their prescribed functions responsive to one or more parameters associated with a subject's respiratory activity including, but not limited to, inspiratory and/or expiratory flow, inspiratory and/or expiratory pressure, tidal volume and symptoms indicative of airway obstruction, e.g., snoring sounds. Some achieve their objectives transthoracically while others deliver air at positive or negative pressure directly to the subject's airway.
  • An early example of such a system, commonly referred to as an “iron lung,” is disclosed in a publication entitled “Mechanical Assistance to Respiration in Emphysema, Results with a Patient-Controlled Servorespirator,” authored by James R. Harries, M.D. and John M. Tyler, M.D., published in the American Journal of Medicine, Vol. 36, pp. 68-78, January 1964. The iron lung proposed in that publication is a respirator designed to apply and remove transthoracic pressure to and from the exterior surface of the body of a subject who sits in a large pressurizable chamber in order to assist the patient's respiratory efforts (i.e., the iron lung applies negative pressure during inspiration and either ambient or positive pressure during expiration). Sophisticated for its day, the apparatus continually controlled the internal chamber pressure in response to the patient's spontaneous respiration, specifically in response to detected respiratory flow or volume. Indeed, a signal obtained from a strain gauge pneumograph fastened around the patient's chest was electrically separated into three components: one proportional to volume, another to inspiratory flow and a third to expiratory flow. Each component was assigned a separate gain control. The component signals are then recombined to control the pressure in the chamber by means of an electrically driven variable valve situated between a blower and the chamber.
  • Although effective for their intended purposes, this and other iron lung devices have generally fallen into disfavor because of their bulk, inconvenience, cost and limited application. That is to say, because of their size and cost such equipment is purchased and maintained essentially exclusively by medical facilities such as hospitals and clinics. Further, iron lungs do not lend themselves to treatment of OSAS and related disorders where comfort and unobtrusiveness are critical for patient compliance and treatment efficacy. This is because negative pressure applied during inspiration compounds the factors that operate to collapse the airway during an inspiratory phase.
  • An essay entitled, “An Apparatus for Altering the Mechanical Load of the Respiratory System,” authored by M. Younes, D. Bilan, D. Jung and H. Krokes, and published in 1987 by the American Physiological Society, pp. 2491-2499, discloses a system for loading and unloading of a subject's respiratory efforts to effect various respiratory responses. The system may load or unload during inspiration, expiration, or both, to assist or resist a subject's spontaneous respiratory activity. The system may apply a continuous positive or negative pressure directly to the subject's airway and loading or unloading occurs via a command signal generated by detected respiratory flow, volume, applied voltage, an external function, or other source.
  • A drawback to this system, however, is that a single resistive gain is chosen for resistive loading or unloading. This single gain is applied to a “half-wave” of the respiratory cycle (either inspiration or expiration) or the “full-wave” thereof (both inspiration and expiration). In other words, under full-wave respiratory loading or unloading, a single chosen gain value is employed during both inspiration and expiration. Thus, a gain that may produce favorable results in regard to reducing breathing work during inspiration, for example, may cause less than desirable or even detrimental consequences during expiration. The converse is true for a gain selected specifically for optimizing expiratory work reduction.
  • In addition, the Younes et al. system operates as a closed, leak-proof system. Hence, to predict its ability to function in an open, leak-tolerant system would be problematic. As such, whether it may be adapted to OSAS treatment, which invariably involves some degree of known and unavoidable unknown system leakage, is suspect.
  • U.S. Pat. No. 5,107,830 to Younes essentially reiterates all of the “breathing assist” (unloading) disclosure that is covered in the Younes, et al. American Physiological Society publication discussed above. In the system disclosed in U.S. Pat. No. 5,107,830, however, the adjustable pressure gain is only realized during inspiration because pressure output is set to zero during exhalation. Additionally, output pressure is calculated as a function of both detected patient inspiratory flow and volume. Furthermore, the system is applicable to COPD but not OSAS therapy.
  • An article entitled “A Device to Provide Respiratory-Mechanical Unloading,” authored by Chi-sang Poon and Susan A. Ward and published in March 1987 in IEEE Transactions on Biomedical Engineering, Vol. BME-33, No. 3, pp. 361-365, is directed to an apparatus which functions somewhat similar to one mode of operation described in both Younes disclosures. That is, the Poon, et al. device may operate to unload a subject's breathing, but only during inspiration. Poon, et al. provide their inspiratory assistance by establishing a positive mouth pressure throughout inspiration in a constant proportion to instantaneous flow. The constant proportion is achieved by (1) selecting a desired gain for a detected positive mouth pressure signal, (2) calculating the ratio of the gain-modified mouth pressure signal over a detected signal reflecting instantaneous flow, (3) comparing the calculated ratio to a selected reference ratio to generate a valve motor control signal, and (4) using the valve motor control signal to operate a motor that drives a servo valve to control the positive pressure applied to the subject's airway. Thus, the apparatus output pressure is determined as a function of both detected pressure and flow. Further, the pressure must be output at a value sufficient to maintain a constant ratio of pressure to flow.
  • A publication entitled “Servo Respirator Constructed from a Positive-Pressure Ventilator,” by John E. Remmers and Henry Gautier, which was published in August, 1976 in the Journal of Applied Physiology, Vol. 41, No. 2, pp. 252-255, describes a modified ventilator that may function as a “demand” respirator generating a transthoracic pressure proportional to phrenic efferent respiratory discharge. Phrenic efferent respiratory discharge is an indication of the outgoing brain signal to the phrenic nerve, which controls diaphragm function. A phrenic efferent respiratory discharge signal causes the diaphragm to contract whereby the subject exerts an inspiratory effort. The phrenic efferent respiratory discharge serves as the apparatus command signal and is processed to produce a moving time average (MTA) and the subject's tracheal pressure serves as a negative feedback signal. Like the Poon et al. device, the Remmers et al. apparatus provides respiratory assistance only during inspiration.
  • An apparatus for automatically regulating the flow and pressure output of a respirator is disclosed in U.S. Pat. No. 3,961,627 to Ernst et al. Like the aforementioned Poon et al. device, however, the Ernst et al. apparatus relies upon an unduly complicated scheme dependent upon detected respiratory pressure and flow in calculating delivered output flow and pressure. More particularly, Ernst et al. propose regulating the delivered flow and pressure of a respiration gas in a respirator during the respiration cycle in which the actual flow and pressure of the respiration gas are measured via a measuring device arranged proximate a patient interface. The measured values are converted into electrical signals and the flow and pressure of the respiration gas are controlled during the inspiration and expiration portions of the respiration cycle via a valve arranged between a respiration gas source and the measuring device. The method for regulating the flow and pressure output comprises (1) measuring the actual flow of respiration gas proximate the patient, (2) measuring the actual pressure of respiration gas proximate the patient, (3) calculating nominal values of flow and pressure from preselected fixed values and the actual values, (4) comparing the actual values measured for the flow and pressure with the nominal values, and (5) obtaining from the comparison a control signal for modulating the valve and thereby regulating the flow and pressure of the respiration gas.
  • Additionally, apart from its utilization of two detected respiratory parameters (flow and pressure) and the complex manner in which these and other variables are reiteratively processed to produce apparatus flow and pressure output, the Ernst et al. system, although capable of delivering a base pressure equivalent to a patient's required end expiratory pressure, is nevertheless unable to deliver any pressure less than the base pressure. Consequently, the Ernst et al. apparatus requires the patient to perform more breathing work than is necessary to satisfy his respiratory needs, especially in the expiratory phase of a respiration cycle, thereby deleteriously affecting the patient's comfort and likelihood of continued compliance with the treatment.
  • In addition to the treatment of breathing disorders, positive airway pressure therapy has been applied to the treatment of congestive heart failure (CHF). In using CPAP on CHF, the effect of the CPAP is to raise the pressure in the chest cavity surrounding the heart. This has the impact of reducing the amount of pressure the heart has to pump against to move blood into the body. By reducing the pressure the heart works against, the work required of the heart is reduced. This allows the sick heart to rest and potentially to get better.
  • The pressure in the chest cavity is also impacted by respiration effort. With inspiration, the pressure in the chest is reduced (negative relative to resting pressure) due to inspiratory effort. This forces the heart to pump harder to move blood into the body. With expiration, the pressure in the chest is slightly increased (positive relative to resting pressure) due to the elastic properties of the chest. This allows the heart to decrease its efforts to pump blood. While conventional CPAP can help the heart rest, it has negative aspects for the patient such as increased work of exhalation and discomfort from the pressure.
  • SUMMARY OF THE INVENTION
  • It is an object of the present invention to provide an uncomplicated system operable to deliver pressurized air to the airway of a patient and readily adaptable to the treatment of OSAS, COPD and other respiratory and/or pulmonary disorders that does not suffer from the disadvantages of conventional pressure application techniques. This object is achieved by providing an apparatus for delivering pressurized breathing gas to an airway of a patient. The apparatus, which is referred to below as a “proportional positive airway pressure” or “PPAP” apparatus, includes a gas flow generator, a patient interface that couples the gas flow generator to the patient's airway, a sensor that detects a fluid characteristic associated with a flow of gas within the patient interface, a pressure controller that regulates the pressure of breathing gas provided to the patient, and a control unit that controls the pressure controller.
  • In an exemplary embodiment, the control unit controls the pressure controller so that the breathing gas is delivered using the gas flow generator and the patient interface. The system determines that the patient is experiencing an apnea and, in response, performs a pressure change maneuver. This maneuver includes increasing a pressure of the flow of gas for a period of time, and decreasing the pressure of the flow of gas after the pressure increase. The system then monitors the change in flow rate for the flow of gas resulting from the pressure change maneuver, if any, and determines whether the airway of the patient is open or closed based on the monitored change in the flow rate.
  • These and other objects, features and characteristics of the present invention, as well as the methods of operation and functions of the related elements of structure and the combination of parts and economies of manufacture, will become more apparent upon consideration of the following description and the appended claims with reference to the accompanying drawings, all of which form a part of this specification, wherein like reference numerals designate corresponding parts in the various figures. It is to be expressly understood, however, that the drawings are for the purpose of illustration and description only and are not intended as a definition of the limits of the invention.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a functional block diagram of an apparatus according to the instant invention;
  • FIG. 2 is a functional block diagram of a further embodiment of an apparatus according to the instant invention;
  • FIGS. 3A and 3B are flow and pressure diagrams, respectively, graphically representing the general manner in which an apparatus according to the instant invention outputs pressurized breathing gas in a proportional relation to the patient flow in both the inspiratory and expiratory phases of a single respiratory cycle;
  • FIGS. 4A and 4B are flow and pressure diagrams, respectively, similar to FIGS. 3A and 3B, exemplifying a number of apparatus output pressure curves that are achieved through selective adjustment of inspiratory and expiratory gain setting controls of the proportional positive airway pressure circuitry of the instant invention;
  • FIGS. 5A and 5B are flow and pressure diagrams, respectively, similar to FIGS. 3A and 3B, contrasting a pressure output curve typical of an apparatus according to the instant invention with pressure output curves of a conventional respiratory assistance apparatus;
  • FIGS. 6A and 6B are flow and pressure diagrams, respectively, similar to FIGS. 3A and 3B, depicting alternative pressure profiles that are employed at the beginning of an inspiratory phase of respiration to facilitate the onset of inspiration;
  • FIGS. 7A and 7B are flow and pressure diagrams, respectively, similar to FIGS. 3A and 3B, illustrating a resultant apparatus pressure output curve according to a further embodiment of the present invention;
  • FIGS. 8A and 8B are flow and pressure diagrams, respectively, similar to FIGS. 3A and 3B, showing a resultant apparatus pressure output curve achieved by combing a conventional bi-level positive airway pressure therapy with the proportional positive airway pressure therapy according to the instant invention;
  • FIGS. 9A and 9B are flow and pressure diagrams, respectively, similar to FIGS. 3A and 3B, reflecting a further resultant apparatus pressure output curve achieved by combining a conventional bi-level positive airway pressure therapy with proportional positive airway pressure therapy according to the instant invention;
  • FIG. 10 is a functional block diagram of a further embodiment of an apparatus according to the instant invention;
  • FIGS. 11A and 11B are flow and pressure diagrams, respectively, similar to FIGS. 7A and 7B, illustrating a resultant apparatus pressure output curve according to a further embodiment of the present invention that utilizes a simplified pressure profile generating technique;
  • FIG. 12 is a pressure diagram illustrating the occurrence of oscillations in the pressure provided to the patient during exhalation;
  • FIG. 13 is a pressure diagram illustrating a first technique for reducing the oscillations illustrated in FIG. 12;
  • FIG. 14 is a pressure diagram illustrating a second technique for reducing the oscillations illustrated in FIG. 12; and
  • FIG. 15 is a pressure and flow diagram illustrating a further technique for handling pressure oscillations during the expiratory phase of the breathing cycle.
  • DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS
  • There is generally indicated at 10 in FIG. 1 a proportional positive airway pressure apparatus according to a presently preferred embodiment of the instant invention and shown in the form of a functional block diagram. Apparatus 10 is operable according to a novel process to deliver breathing gas, such as air, oxygen or a mixture thereof, at relatively higher and lower pressures (i.e., generally equal to or above ambient atmospheric pressure) to a patient 12 in proportion to the patient's respiratory flow for treatment of OSAS, snoring, CHF, COPD and other respiratory or cardio-respiratory disorders.
  • Apparatus 10 includes a gas flow generator 14, such as a conventional CPAP or bi-level PAP blower, i.e., a centrifugal blower, that receives breathing gas from any suitable source, e.g., a pressurized bottle 16 of oxygen or air, the ambient atmosphere, or a combination thereof. The gas flow from flow generator 14 is passed via a delivery conduit 18 to a breathing appliance or patient interface 20 of any suitable known construction that is worn by patient 12. In an exemplary embodiment of the present invention, the conduit 18 is a large bore flexible tube and the patient interface 20 is either a nasal mask or a full face mask, as shown. Other breathing appliances that may be used in lieu of a mask include a mouthpiece, a nasal seal, nasal prongs or cannulae, an endrotracheal tube, a trachea adapter or any other suitable appliance for interfacing between a source of breathing gas and a patient. Also, the phrase “patient interface” can encompass more that the interface worn by the patient. For example, the patient interface can include delivery conduit 18 and any other structures that connect the source of pressurized breathing gas to the patient.
  • The apparatus also includes a sensor, such as a flow transducer 22 or similar flow sensing element, situated within or near the breathing circuit, i.e., the patient interface 20, conduit 18 or gas flow generator 14. Flow transducer 22 may be any suitable gas flow meter, such as, for example, a bidirectional dynamic mass flow sensor. Preferably, however, the flow transducer is a pressure responsive sensor for detecting the magnitude of the pressure gradients between the inlet of the patient's airway and his lungs. Within the scope of the present invention, flow and respiratory pressure gradient are highly correlated.
  • It is to be understood that the flow sensor need not be coupled directly to conduit 18. On the contrary, the present invention contemplates the use of any sensor or a plurality of sensors that can measure the flow of breathing gas in the conduit. For example, flow in the system can be measured at the patient interface device or can be measured or estimated from the motor or piston speed, power, current, torque, or feedback control used to provide the elevated pressure by flow generator 14. Thus, the sensor need not be a direct flow measurement, but can be determined indirectly from measurements associated with the flow generator. In short, the present invention contemplates any conventional technique for measuring the flow of gas delivered to the patient as flow transducer 22.
  • In accordance with a presently preferred embodiment, the flow transducer 22 is interposed in line with conduit means 18, most preferably downstream of a pressure controller 24. The flow transducer generates output signals that are provided, as indicated by reference numeral 26, to PPAP circuitry 28 described in greater detail hereinafter. The output signals include first flow rate signals indicative of inspiration by the patient and second flow rate signals indicative of the patient's expiration. The signals are continuously transmitted and correspond to the instantaneous flow rate of breathing gas within conduit means 18.
  • In addition, the output from flow transducer 22 is also desirably provided, as indicated by reference numeral 30, to an optional leak detecting system 32. A suitable leak detector for present purposes is that disclosed in U.S. Pat. No. 5,148,802, the disclosure of which is incorporated herein by reference. However, other techniques for substantially instantaneously calculating system leakage, including both known leakage, such as that discharged through a mask exhaust port 34, and unknown leakage, such as that at various conduit couplings or at the patient contact site of the patient interface 20, are acceptable. With any non-invasive embodiment of the present invention, i.e., not involving an endrotracheal tube or trachea adapter, the patient flow must be estimated taking into account the aforesaid known and unknown system leaks.
  • The output signal from the leak detecting system 32 is provide, as at 36, to PPAP circuitry 28. In this way, the PPAP circuitry logic continuously compares the output from flow transducer 22 with that from leak detecting system 32 to discriminate that portion of system flow associated with the patient's respiration from that caused by system leakage. As a result, PPAP circuitry 28 more precisely controls the output of the pressure controller 24 as a function of patient respiratory flow, rather than overall system flow.
  • If formed as a mask, as illustrated, patient interface 20 commonly includes, as mentioned above, a suitable exhaust system, schematically indicated at 34, to exhaust breathing gases during expiration. Exhaust system 34 preferably is a continuously open port that imposes a suitable flow resistance upon exhaust gas flow to permit pressure controller 24, located in line with conduit 18 between flow generator 14 and patient interface 20, to control the pressure of air flow within the conduit and thus within the airway of the patient. For example, exhaust port 34 may be of sufficient cross-sectional flow area to sustain a continuous exhaust flow of approximately 15 liters per minute at a system pressure of 10 cm H2O. The flow via exhaust port 34 is one component, and, typically, the major component of the overall system leakage, which is an important parameter of system operation. In an alternative embodiment, it has been found that a non-rebreathing valve may be substituted for the continuously open port.
  • Pressure controller 24 controls the pressure of breathing gas within conduit 18 and thus within the airway of the patient. Pressure controller 24 is located preferably, although not necessarily, downstream of flow generator 14 and may take the form of an adjustable, electronically-controlled valve. Of course, other method of pressure control are contemplated by the present invention, such as controlling the operation of the pressure generator, either alone or in combination with a pressure control valve. For example, one embodiment of the present invention contemplates that the pressure generator is a blower, which includes an impeller mounted in a housing and rotated by a motor. In this embodiment, the pressure controller is a control system that controls the operating speed of the motor in the blower without the need for a dedicated flow control valve.
  • Apparatus 10 also desirably includes a safety circuit, preferably comprising an adjustable maximum pressure setting control 38 and an adjustable minimum pressure setting control 40 operatively connected to pressure controller 24. The safety circuit allows the manufacturer, the patient or his overseeing health care professional to selectively establish minimum and maximum system output pressures below and above which the system will not dispense pressurized gas. The minimum pressure will, of course, be at least zero and, preferably, a threshold pressure sufficient to maintain pharyngeal patency during expiration. The maximum pressure, on the other hand, will be a pressure somewhat less than that which would result in over-inflation and perhaps rupture of the patient's lungs. The safety circuit functions differently than the pressure controls which determine, for instance, the CPAP prescription pressure or the IPAP and EPAP prescription pressures used in bi-level PAP therapy. That is, instead of establishing lower and upper prescription pressures to be administered during normal usage of the apparatus (subject to the influence of the PPAP circuitry 28), the maximum and minimum pressure setting controls 38 and 40 set absolute minimum and maximum fail-safe output pressure limits which are not to be exceeded. Thus, the danger of potential physical harm to the patient in the even of malfunction of other system components, e.g., the prescription pressure controls, is effectively eliminated.
  • PPAP circuitry 28, according to the present invention, is subject to the influence of additional essential controls, including a base pressure control 42, an inspiratory gain setting control 44, and an expiratory gain setting control 46. The base pressure control 42 establishes a base pressure (Pbase), usually greater than or equal to zero and conceptually equal to the EPAP level in bi-level therapy, sufficient to maintain airway patency at the beginning and end of exhalation. The inspiratory gain setting control 44 permits selection of a resistive gain (GainInsp) to be applied to the detected inspiratory flow. Similarly, the expiratory gain setting control 46 enables selection of a resistive gain (GainInsp) to be applied to the detected expiratory flow.
  • In a broad sense, PPAP therapy and the PPAP apparatus 10 constitute a novel system providing pressure to a patient via nasal, nasal/oral, oral, or trachea interface to treat OSAS, COPD and other breathing disorders. The pressure delivered to the patient is a function of the patient flow rate. The function can be described as follows:

  • Pdelivered=Pbase+Gain*Flow
  • where:
    “Pdelivered” is the pressure delivered to the patient interface;
    “Pbase” is the base line pressure (greater than or equal to zero and conceptually equal to EPAP);
    “Flow” is the estimated patient flow rate determined by the flow transducer; and
    “Gain” is the constant used to augment pressure based on the flow rate. The gain constant can further be refined to allow one constant for inspiration (positive flow) and a different constant for exhalation (negative flow).
  • FIGS. 3A and 3B represent flow and pressure diagrams, respectively, graphically depicting the manner in which apparatus 10 outputs pressurized breathing gas in proportional relation to patient flow, as detected by flow transducer 22, in both the inspiratory and expiratory phases of a respiratory cycle. The pressure curve of FIG. 3B reflects a situation where the same gain is chosen for both inspiratory and expiratory flow. Conceivably, essentially the same pressure curve may be generated by the apparatus disclosed in the aforementioned essay entitled “An Apparatus for Altering the Mechanical Load of the Respiratory System,” by Younes, et al. which may use a single resistive gain applicable to both inspiration and expiration.
  • With PPAP apparatus 10, however, separate and independent gains may be chosen for inspiration and expiration, whereby gains best suited to optimizing performance, i.e., minimizing breathing work, may be precisely matched with each of the inspiratory and expiratory phases. Thus, the function of the apparatus described in the Younes et al. article corresponds to a special and relatively limited application of the present invention where the selected inspiratory and expiratory gains are identical.
  • As is far more often the case, however, an optimum inspiratory gain is not the optimum expiratory gain and vice versa. Thus, the pressure output of the PPAP apparatus 10 is more accurately described according to the following functions, which functions can be encoded into the PPAP circuitry 28.

  • Pinhalation=Pbase+GainInsp*Flow,

  • and

  • Pexhalation=Pbase+GainExp*Flow,
  • where:
    “GainInsp” is the constant used during inspiration (positive flow) to boost pressure based on the flow rate; and
    “GainExp” is the constant used during exhalation (negative flow) to reduce pressure based on the flow rate.
  • The gain typically selected has a range of about 0 to 10 cm H2O/liter/second for inspiration. The gain chosen for exhalation is normally lower than the inspiratory gain, e.g., values in the range of 0 to 4 cm H2O/liter/second, although higher gain values may be chosen for inspiration and/or expiration, if such is desired or necessary.
  • Regardless of the chosen gain values, applying a flow signal derived from a normal respiratory pattern will result in a pressure rise above Pbase during inspiration and will drop below Pbase during exhalation. When patient flow is near zero, i.e., at the beginning and end of inspiration, as well as the beginning and end of exhalation, the output pressure approaches Pbase.
  • FIGS. 4A and 4B perhaps most clearly exemplify the effect that the selection of different gains for both the inspiratory and expiratory phases of a respiratory cycle has upon the pressure output curve. GainInsp(a), GainInsp(b), GainInsp(c) and GainInsp(d) represent, in descending order, several of an infinite range of gain values that may be applied during inspiration. Similarly, GainExp(e), GainExp(f), GainExp(g) and GainExp(h) indicate increasing expiratory gain values. With different gain settings, any number of wave forms can be generated. For example, a high setting may be established for GainInsp and a low setting for GainExp, or vice versa, or the gain settings for inspiratory flow and expiratory flow may be the same.
  • In one embodiment of the present invention, PPAP therapy seeks to provide only the pressure that is necessary to prevent airway collapse at any given moment during the breathing cycle. This will generally result in supplying, at appropriate times, maximum pressure only when peak negative airway inspiratory pressures are detected and minimum pressure only when peak positive airway exhalation pressures are detected. At all other times during the breathing cycle, the PPAP apparatus delivers air at a variable pressure responsive to the patient's respiratory efforts in a range between the maximum and minimum pressures. As mentioned above, PPAP therapy also involves the administration of a base pressure of zero or greater to which the product of a selected gain times instantaneous flow (inspiratory and expiratory) is continuously added to produce the instantaneous output pressure of the PPAP apparatus. An identical gain may be selected for inspiration and expiration, or different gain values may be independently selected for inspiration and expiration. The base pressure will be the pressure necessary to overcome any mechanical collapsing forces that result from the structure of the airway tissues, muscle tone, and body position. In other words, the base pressure is generally equivalent to the expiratory positive airway pressure or “EPAP” typically used in bi-level PPAP therapy.
  • In this connection, FIG. 5B illustrates the pressure output curve generated by the PPAP apparatus 10 vis-a-vis conventional CPAP and bi-level PAP apparatus over a single respiratory cycle. So long as the appropriate inspiratory and expiratory splint pressures are applied at point 48 (peak inspiratory flow), point 50 (beginning of exhalation) and point 52 (end of exhalation), less pressure may be provided at all other times during the breathing cycle than is normally supplied by conventional CPAP or bi-level PAP therapy. This reduced output pressure is represented by the “PPAP” curve of FIG. 5B. The hatched areas of that figure reflect the difference in pressures provided by PPAP and the IPAP and EPAP phases of bi-level PAP during a typical respiratory cycle. The hatched areas may be conceptualized as the respiratory work or effort savings that are attributed to PPAP. This work savings, as would be expected, translates to greater comfort for the PPAP assisted patient and increased compliance with the respiratory treatment. According to the present invention, PPAP therapy thus represents a novel respiratory disorder treatment by which patient comfort (and, therefore, treatment compliance) exceed that offered by either CPAP or bi-level PAP therapy.
  • Referring again to FIG. 1, it will thus be appreciated that pressure controller 24 is continuously governed by and outputs variable pressure responsive to a command signals 54 from PPAP circuitry 28. Command signals 54, in turn, are the product of the influences of one or more of the outputs from flow transducer 22, leak detection system 32, base pressure control 42, inspiratory gain setting control 44, expiratory gain setting control and, in an alternative embodiment, a pressure profile control 56 discussed below.
  • In normal breathing, a negative pressure gradient must be generated before flow can begin. Hence, the negative pressure waveform generated in the airway must precede and thereby induce inspiratory flow at the start of inspiration. In an unstable airway, which is characteristic of OSAS, for example, this asynchronous relationship of negative pressure gradient and inspiratory flow onset would, if not accommodated by suitable compensatory measures, lead to a situation where the PPAP therapy would not generate sufficient pressure (due to low flow) to overcome the negative pressure in the airway, whereby total or partial airway collapse may result. This problem can be solved by a number of methods. For instance, a higher PPAP base pressure can be used to provide additional pressure to support the airway at the beginning of inspiration. Alternatively, however, as demonstrated by FIGS. 6A and 6B, a temporary pressure increase can be added at the start of inspiration to support to the airway until sufficient flow is generated to drive the PPAP process. The present invention offers several viable approaches by means of which pressure can be added during the initial phase of inspiration to support the airway as inspiratory flow increases.
  • Temporary pressure increases may be effected using pressure profile control 56 in operative connection with PPAP circuitry 28 to select a desired elevated pressure waveform in the early stages of inspiration. In this regard, pressure profiles may be used as minimum values for the output pressure at the outset of inspiration, thereby giving rise to the following alternative equations for available output pressure during inspiration.

  • Pinhalation=greater of:

  • Pbase+GainInsp*Flow

  • or

  • Pbase+Pprofile
  • where:
    “Pinhalation” is the pressure delivered to the patient interface during inspiration “Pbase” is the base line pressure (conceptually equal to EPAP);
    “Flow” is the estimated patient flow;
    “GainInsp” is the constant used during inspiration (positive flow) to boost pressure based on the flow rate; and
    “Pprofile” is a function that generates a pressure profile to support the airway at the start of inspiration. Such pressure profile functions may be constant, e.g., a step profile as shown by the dotted line identified by numeral 58 in FIG. 6B, time based (for instance, a backwards ramp profile as shown by the dotted and dashed line identified by numeral 60 in FIG. 6B), or any other functional shape.
  • Alternatively, pressure profiles can be used exclusively to control the output pressure for a predetermined initial segment of inspiration. The following equations represent system output pressure during inspiration under such control conditions.

  • Pinhalation=Pprofile from start of breath to X

  • and

  • Pinhalation=Pbase+GainInsp*Flow from X to start of exhalation
  • where:
    “Pinhalation” is the pressure delivered to the patient interface during inspiration;
    “Pbase” is the base line pressure (conceptually equal to EPAP);
    “Flow” is the estimated patient flow;
    “GainInsp” is the constant used during inspiration (positive flow) to boost pressure based on the flow rate; and
    “Pprofile” is any function that generates a pressure profile to support the airway at the start of inspiration. Such functions could be constant, such as, for example, a step profile, or time based, such as a backwards ramp profile, or any other functional shape. “X” is a preselected transition point determined by time, or analysis of the flow signal, such as curvature, percent drop from peak flow rate, integration, derivative, analysis of prior breaths or a combination of flow analysis and time.
  • The PPAP apparatus 10 also has the capacity to measure and store in a memory 62 (FIG. 1) the following parameters: tidal volume, inspiratory time, expiratory time, peak pressure, peak flow, 02 saturation (as a voltage input from an external source), plural pressure (as a voltage input from an outside source), mask pressure, estimated leakage, and system parameters, e.g., Pbase, Auto GainInsp, GainInsp, GainEsp, IPAP and EPAP. It is to be understood that this list is not exclusive; other parameters can be stored in memory 62.
  • A further method by which the present system addresses the problem presented by the changing needs of the patient is to combine the beneficial features of PPAP with a more controlled therapy such as CPAP, as is shown in FIGS. 7A and 7B.
  • With CPAP, a single pressure is generated and delivered throughout the sleeping session. PPAP can be advantageously joined with CPAP to lower the pressure provided to the patient during exhalation. The resulting equations for pressure delivered under combined PPAP-CPAP are as follows:

  • Pinhalation=CPAP

  • and

  • Pexhalation=CPAP+GainExp*Flow
  • where:
    “GainExp” is the constant used during exhalation (negative flow) to reduce pressure based on the flow rate.
  • It should be noted that the CPAP pressure for this embodiment can be fixed for all time during the therapy session or it can vary over the course of the treatment session. For example, it is known to provide a patient with an auto-titrating CPAP pressure, where the CPAP pressure is varied based on the monitored condition of the patient, the condition of the pressure support system, or both. Thus, the present invention contemplates combining PPAP during exhalation with an auto-titrating CPAP pressure during inhalation, so that the CPAP pressure is determined using any conventional auto-titration technique, such as that taught by U.S. Pat. Nos. 5,203,343; 5,458,137 and 6,087,747 all to Axe et al. or U.S. Pat. No. 5,645,053 to Remmers et al.
  • It has further been discovered that patient comfort can be increased when using the PPAP-CPAP combination. It can happen when using conventional triggering techniques, that the trigger from inspiration to expiration is detected before the patient's flow reaches zero. In other words, the patient's expiratory effort begins, not at the zero flow point, but at a period of time slightly before that point. For example, at point “p” in FIG. 7A the pressure support system may consider the patient to be in the expiratory phase of the breathing cycle.
  • If Pexhalation is calculated at point “p”, where the patient flow is positive, the patient would receive an increase in pressure, when they should be getting a decrease in pressure or “pressure relief”. This can be avoided by delaying the calculation of Pexhalation until the flow actually goes below zero. However, the patient may perceive a delay in the pressure relief. Therefore, a further embodiment of the present invention contemplates calculating Pexhalation at the trigger from inspiration to expiration as follows:

  • Pexhalation=CPAP+GainExp*(Flow−FlowOffset),
  • where “Flow” is the current patient flow and “FlowOffset” corresponds to the last value of patient flow (if positive) during inspiration. In essence, the FlowOffset value allows Pexhalation to be calculated at point “p” in FIG. 7A, but accounts for the fact that the flow is positive at this point by subtracting out an equal or greater amount of flow using the FlowOffset value. Pexhalation is calculated using the FlowOffset only if the Flow is positive. Otherwise, the FlowOffset can be removed or set to zero.
  • The value of FlowOffset must be decreased during the expiratory phase to ensure that the offset reaches zero by the end of expiration, i.e., when the patient's flow increases back to zero, so that the pressure relief returns to zero at that time. The decrease on FlowOffset can be done periodically or continuously throughout the expiratory phase.
  • FIGS. 8A and 8B demonstrate that PPAP can also be combined with bi-level PAP therapy in a number of ways to produce effective therapeutic pressure waveforms. One application, generally similar to the aforementioned PPAP-CPAP scenario, is to use PPAP to lower the pressure during exhalation. The resulting equations for the delivery of composite PPAP-bi-level PAP pressure are as follows:

  • Pinhalation=IPAP

  • and

  • Pexhalation=EPAP+GainExp*Flow
  • where:
    “GainExp” is the constant used during exhalation (negative flow) to reduce pressure based on the flow rate.
  • Another approach to merging PPAP with bi-level therapy is shown in FIGS. 9A and 9B where IPAP is applied to the patient for a first portion of the inspiratory cycle and PPAP is applied for the remainder of the breathing cycle. GainInsp is automatically calculated for each breath based on IPAP and the flow rate as follows:

  • Pinhalation (t 0 to t 1)=IPAP

  • and

  • Pinhalation (t 1 to t 2)=Pbase+AutoGainInsp*Flow

  • and

  • Pexhalation=Pbase+GainExp*Flow
  • where:
    “Flow” is the estimated flow rate;
    “t0” is the time at the start of breath;
    “t1” is the time when the estimated flow rate is a predetermined percentage of peak inspiratory flow rate;
    “t2” is the time at the start of exhalation;
    “IPAP” is a continuously applied inspiratory positive airway pressure;
    “Pinhalation (t0 to t1)” is the pressure delivered to the patent from t0 to t1;
    “Pbase” is a continuous base pressure;
    “AutoGainInsp” equals (IPAP−Pbase)/Flow at t1;
    “Pinhalation (t1 to t2)” is the pressure delivered to the patient from t1 to t2;
    “GainExp” is the constant used during exhalation to reduce pressure delivered to the patient; and
    “Pexhalation” is the pressure delivered to the patient during exhalation.
  • It is to be understood that the flow and PPAP pressure output curves of FIGS. 3A through 9B represent the apparatus output pressure and flow during the inspiratory and expiratory phases of a single respiratory cycle. The PPAP and flow curves can, of course, be expected to vary somewhat from respiratory cycle to respiratory cycle depending on the patient's respiratory requirements, particularly under fully automated PPAP therapy described hereinafter. Furthermore, somewhat greater variations will likely occur between the respiratory cycles associated with different stages of an extended treatment session, especially during OSAS treatment.
  • FIG. 2 represents a further preferred embodiment of a PPAP apparatus pursuant to the present invention, designated herein by reference numeral 10′. Apart from the addition IPAP/EPAP (bi-level PPAP) circuitry 64, PPAP apparatus 10′ is identical in structure and function to PPAP apparatus 10. According to this embodiment, output 66 from flow transducer 22 is fed to bi-level PAP circuitry 64. Bi-level PAP circuitry 64 may assume any conventional form such as, for example, that described in U.S. Pat. Nos. 5,148,802; 5,433,193; and 5,632,269, the contents or which are incorporated herein by reference. Output 68 from bi-level PPAP circuitry 64 is transmitted to the PPAP circuitry 28. Output 68 consists of an IPAP signal if the patient is inhaling and an EPAP signal in the event the patient is exhaling. The logic of the PPAP circuitry 28 utilizes this input according to a preselected one any of the aforementioned combinations of PPAP-bi-level therapy to generate a desired pressure command signal 54.
  • Pursuant to the present invention, the pressure delivered to the patient is determined by the base pressure, the flow rate and the gain (and the pressure profile if used). For a given patient condition, these settings can be adjusted as necessary to stabilize the airway. In OSAS, a patient's periodic and, to a lesser extent, instantaneous condition is variable with sleep state and body position. Thus, settings that may work well in during one portion of a sleeping session may not work as well at a different time. In other words, settings that support the airway at its most unstable state may cause pressures that are higher than necessary during more stable times. Likewise, settings that work well at one point in the session may be insufficient at another time.
  • The present invention proposes several methods to minimize the impact of the patient's changing needs on the optimization of PPAP therapy. One such method is to automatically adjust the gain, pressure profile and baseline pressure to meet the patient's demands. This adjustment can be based on analysis of patient parameters related to flow, e.g., magnitude, shape, derivative, integral (volume), pressure, snoring, arterial oxygen saturation, exhaled C02, airway diameter, or other parameters.
  • Using one or more of these parameters the system may adjust the GainInsp to prevent partial airway obstruction (hypopnea). The goal of such systems is to increase GainInsp responsive to any of the following patient conditions:
  • decreased inspiratory flow;
  • decreased inspiratory volume;
  • increased airway resistance, as determined by flow or pressure signal analysis;
  • airway instability, as indicated by pressure or sound variations;
  • drops in arterial oxygen saturation; or
  • decreases in airway diameter.
  • The apparatus according to the invention may also maintain minimal GainInsp in the absence of these conditions.
  • The present system may also adjust the base pressure (Pbase) to prevent complete collapse of the airway (apnea) or severe collapse (severe hypopnea). Apnea can be detected by analysis of the flow signal and/or by using reflected pressure waves, or a combination of pressure and flow to determine airway patency. Moreover, it may be important to determine if the apnea is caused by airway collapse or by a lack of respiratory drive. If an obstructive event is detected the base pressure can therefore be increased to open the airway. A further capability of the present system is to maintain a minimum Pbase in the absence of these conditions.
  • The system may also adjust the pressure profile (Pprofile) to prevent apnea or hypopnea at the onset of inspiration. As such, the system may increase Pprofile in response to decreased inspiratory flow, decreased respiratory volume, flow waveform shape analysis that indicates increasing airway resistance, pressure or sound variations indicative of airway instability, drops in arterial oxygen saturation, decreases in airway diameter or a change in exhaled C02. Commensurate, therewith, the present invention also functions to maintain the minimum pressure profile in the absence of these conditions.
  • FIG. 10 reveals a presently preferred embodiment of a fully automated PPAP apparatus 10″ constructed according to the present invention. Generally similar in structure and function to PPAP apparatus 10 of FIG. 1, PPAP apparatus 10″ additionally incorporates a microprocessor or central processing unit (CPU) 70 that preferably utilizes an output signal 72 from flow transducer 28 as a continuous feedback signal to enable the CPU to continuously adjust Pbase, Pprofile, GainInsp, and GainExp as necessary. The CPU may, however, be configured to effect its continuous system control functions responsive to any of the aforementioned patient parameters related or unrelated to respiratory flow.
  • Apparatus 10″ also has the capability to detect hypopnea, as evidenced by decreases in peak flow and/or tidal volume for a given period of time, and the occurrence of apneas, as manifested by very little flow for a given period of time. To detect hypopnea, for example, the CPU 70 may be programmed to make a comparison between a short term average of peak inspiratory flow rate or tidal volume (e.g., a 3 breath average) and a long term average of peak flow rate or tidal volume (e.g., greater than 20 breaths). If a decrease of greater than 25% is detected the system determines a hypopnea to be present. This determination is desirably made only if the leakage is well estimated and stable. Thus, large changes in leak or initiation of a leak recovery will cause data to be ignored.
  • The invention further includes a method for determining if the airway is open (central apnea) or obstructed (obstructive apnea) during an apnea. Once an apnea of significant duration is detected the system, under the direction of CPU 70, automatically increases GainInsp by 2 cm H2O, waits approximately 1 second and decreases the pressure back to the original value. If there is a significant change in flow during this pressure change, the system concludes that the airway is open (central apnea). If there is no significant change in flow the system determines that the airway is obstructed (obstructive apnea). The system will continue to monitor each apnea for its entire duration at periodic intervals to determine the nature of the apnea.
  • In accordance with a preferred embodiment, the PPAP apparatus 10″ controls are automatically adjusted as follows. In the event of a hypopnea, GainInsp is increased by 2 cm/liter/second. In the event of an obstructive apnea, Pbase is increased by 1 cm H2O. The device will continue to increase Pbase as long as an obstructive apnea of significant duration is detected. The device will not increase GainInsp again, if necessary, until 5 breaths have passed. If no hypopnea or apneas occur over a period of 30 breaths, GainInsp is decreased by 1 cm/liter/second. If no hypopnea or apneas occur over a period of 50 breaths, Pbase is decreased by 1 cm H2O. In addition, the apparatus may control the delivery of 02 while patient flow is greater than zero, if such desired or necessary.
  • Although not illustrated, still further embodiments of the present invention contemplate the incorporation of fully automated PPAP with CPAP and/or bi-level PAP therapy. In these cases CPAP or IPAP may be controlled using the same logic that controls GainInsp in the above-described fully automated PPAP system. Likewise, Pbase may be controlled in a similar manner to that described in connection with fully automated PPAP.
  • The fully automated PPAP-CPAP or PPAP-bi-level PAP systems may also adjust Pprofile to prevent apnea or hypopnea at the start of inspiration. Such systems may therefore increase CPAP (or IPAP) or Pprofile in the face any of the following patient conditions:
  • decreased inspiratory flow;
  • decreased inspiratory volume;
  • increased airway resistance, as determined by flow or pressure signal analysis;
  • airway instability, as indicated by pressure or sound variations;
  • drops in arterial oxygen saturation; and
  • decreases in airway diameter.
  • It will be understood that CPAP or IPAP would be maintained at minimal levels in the absence of these conditions.
  • Using PPAP therapy, therefore, it is additionally possible to employ PPAP in response to expiratory flow to reduce pressure applied during expiration to less than the patient's PEEP level throughout all but the end of the expiratory phase in a manner similar to that described for lowering the pressure below Pbase during exhalation in the treatment of OSAS. This lowering of applied pressure to less than PEEP during the expiratory phase diminishes breathing work and enhances patient comfort when compared to the constant expiratory phase pressure applied during EPAP. Indeed, PPAP can be adapted to any ventilation mode that uses PEEP. Such applications may include pressure support with PEEP, PAV with PEEP or other applications of PEEP in respiratory assistance therapy.
  • As noted above, the present invention contemplates providing different inspiratory gains or expiratory gains depending on the pressure support needs of the patient. See, e.g., FIG. 4B and the associated text. A further embodiment of the invention contemplates allowing the patient to select the gain (inspiratory or expiratory) so that the user can try different gains to determine which gain provides the best pressure support therapy. It can be appreciated that this embodiment is best suited for allowing the patient to select the expiratory gain, such as when using the PPAP-CPAP combination, because it is commonly accepted that the inspiratory positive pressure, and, hence, the inspiratory gain, should be set by a physician and should not be altered by the patient.
  • For example, the present invention contemplates having a user select a first expiratory gain setting and use the pressure support system at that gain. The efficacy, comfort, or both of the pressure support system operating at the first gain, can then be monitored using any conventional technique, such as by having the patient complete a questionnaire. See, for example, published PCT application publication no. WO00/18347, which teaches a technique for providing a pressure support system and an efficacy questionnaire. In a subsequent therapy session, the user selects a second expiratory gain different than the first. The efficacy, comfort, or both of the pressure support system operating at the second gain can then be monitored and compared against the results garnered using the first gain. This process can be repeated using still other gains. In this manner, the optimal gain can be determined. The present invention also contemplates allowing the user to adjust the base pressure to determine its optimum level using the above-described technique.
  • The present invention further contemplates that the above-described patient-feedback determination of the optical gain or base pressure can be performed automatically. For example, the pressure support system can be programmed to automatically provide different gains or base pressures during different therapy sessions. After each session the user can be prompted to take a survey to gauge the effectiveness, comfort, or both of that therapy session. After sufficient data is collected the system can then automatically select the gain or base pressure based on the survey results that is optimum for that patient.
  • Furthermore, the administration of oxygen in phase with inspiration may also easily be included with PPAP therapy for the treatment of COPD patients requiring supplemental oxygen.
  • The present invention also contemplates that the pressure of the gas being provided to the patient can be controlled so as to vary over time. For example, in one embodiment of the present invention, the pressure provided to the patient increases from a first minimum pressure to a desired therapy pressure over a period of time. This ramp increase in pressure provides the patient with time to fall asleep under relatively low pressure that is increased to the therapy pressure over time. Thereafter, the pressure increases so that the therapy pressure is being applied after the patient is asleep. A reverse process can be performed in the morning, with the pressure being decreased from the therapy pressure shortly before the patient intends to wake up. Ramp control 120 in FIG. 10 schematically illustrates a manually actuated controller that provides commands to PPAP circuitry 28 to cause the pressure to be provided according to a ramp cycle. Furthermore, the ramp control may be adjusted according to the output of CPU 70. Ramp control 120 can be used to set the parameters associated with the ramp function, such as the ramp period, ramp start time, ramp stop time, and ramp shape.
  • Examples of techniques for controlling the pressure level provided to the patient via one or more ramp functions, as well as other methods for controlling the patient pressure, are disclosed in U.S. Pat. Nos. 5,492,114; 5,551,418 and RE 35,295, the contents of each are incorporated herein by reference. Many of the techniques taught by these patents can be incorporated into the present apparatus and method to provide the optimum therapy necessary to treat the patient.
  • In a still further embodiment of the present invention, an alarm 122 is coupled to PPAP circuitry 28 and/or CPU 70. Alarm 122 can be controlled so as to be actuated as a result of a variety of circumstances. However, in a preferred embodiment of the invention, alarm 122 is actuated responsive to an automatically determined gain falling outside a predetermined range of values.
  • The present invention also contemplates limiting a value for an automatically determined gain, such as AutoGainInsp discussed above, to prevent the automatically determined gain from exceeding predetermined limits, for example, from exceeding limits that may result in an excessively high pressure being provided to the patient. The limits on the amount that the gain can themselves be altered so that these limits vary over a predetermined period of time. Also, the amount of change that may take place in the automatically determined gain over a predetermined period of time can also be controlled, thereby preventing the automatically determined gain from changing by more than a predetermined amount over the predetermined period of time.
  • In using PPAP to treat CHF, the present invention reduces mean pressure and work of exhalation while still providing the same level of rest to the heart. By applying a positive base pressure substantially equivalent to a pressure needed to reduce cardiac preload and afterload (preferably in the range of 5-10 cm H2O), the present invention helps the heart reduce its efforts. With additional positive pressure during inspiration in proportion to respiratory effort, one can overcome the effect of negative pressure being produced during inspiration. PPAP is particularly appropriate in CHF patients in that the typical CHF patient has normal lung compliance. In these patients, much of the respiratory loading can be inferred from the flow signal. By reducing the pressure below the base pressure during exhalation, one can reduce the work of exhalation without, reducing the benefit to the heart. The net effect will be the same benefit to the heart with reduced work of breathing and lower mean pressure.
  • Similar to PPAP therapy's use for preventing airway collapse, PPAP therapy for the treatment of CHF delivers only the minimum amount of pressure needed to reduce cardiac preload and afterload. This will result in supplying a base pressure to the exterior of the heart equivalent to the pressure needed to reduce cardiac preload and afterload in the absence of respiratory loading and a varying pressure which is needed to overcome the impact of respiratory loading on cardiac preload and afterload while minimizing the work of breathing.
  • Supplying positive pressure to the exterior of the heart via the respiratory system has two benefits firstly, the positive pressure will reduce the enlarged heart of a CHF patient to a size closer to normal. This return to normal size, allows the muscles of the heart to work more effectively. Secondarily, the positive pressure in the chest cavity reduces the amount of pressure the heart must overcome to pump blood to the rest of the body.
  • The heart and chest cavity are at the same pressure. Typically this pressure fluctuates about ambient pressure due to the impact of respiratory loading. The circulatory system has a working pressure that varies as the heart pumps but averages 100 mm HG in normal-tensive patients. The heart must supply the power to force blood from the chest cavity into the pressurized circulatory system. Increasing the pressure in the chest cavity reduces the amount of pressure the heart must over come to pump blood. A pressure in the chest cavity of 10 cm H2O or approximately 10 mm Hg will reduce the load on the heart by 10 mm Hg/100 mm Hg or roughly 10%.
  • The impact of respiratory effort on the heart is as follows: during inspiration, the pressure in the chest (and thus surrounding the heart) becomes more negative relative to the rest of the body. This increased negative pressure increases the amount of pressure the heart must generate to pump blood from the chest cavity to the body. By providing pressure in excess of the base pressure during inspiration, PPAP is able to offset this decrease in chest cavity pressure and maintain a relatively constant pressure in the chest.
  • During exhalation the pressure in the chest becomes less negative relative to the rest of the body. By reducing the pressure during exhalation, PPAP is able to offset the increase in chest cavity pressure and maintain a relatively constant pressure in the chest.
  • By minimizing the decrease in pressure and taking advantage of the increased pressure during exhalation, the variable portion of PPAP allows a lower baseline to be set relative to using a constant pressure with the same benefits to the heart. This lower baseline and reduced pressure during exhalation also reduces the work of breathing and increases patient comfort.
  • It is further desirable to implement a version of PPAP similar to that discussed above with respect to FIG. 7 on existing CPAP devices. Providing a version of PPAP on existing CPAP devices enhances the patient comfort and, hence, compliance without the significant financial and other burdens appurtenant to manufacturing and introducing a new CPAP device that includes a PPAP mode. Providing a PPAP therapy on a CPAP device can be accomplished in a variety of ways, such as that discussed above with respect to FIGS. 7A and 7B.
  • A version of PPAP can be implemented on a CPAP system in a more cost effective manner if the reactive component used to generate the reduced pressure curve during exhalation in FIG. 7 is replaced with a defined reduced pressure profile. This pressure profile replaces the constant CPAP pressure otherwise applied by the CPAP device during the expiratory phase of the patient's breathing cycle. In an preferred embodiment of the present invention, the defined pressure profile has a shape that generally corresponds to a patient's normal flow.
  • FIGS. 11A and 11B are flow and pressure diagrams similar to FIGS. 7A and 7B illustrating a resultant apparatus pressure output curve according to a further embodiment of the present invention that utilizes a simplified pressure profile generating technique. Flow signal 80 in FIG. 11A illustrates the patient's inspiratory phase 82 and expiratory phase 84. As shown in FIG. 11B, a continuous CPAP pressure 86 is delivered during the inspiratory phase 82. During the expiratory phase, the pressure support device is controlled to deliver a reduced pressure following a predetermined pressure profile 88. The resulting equations for pressure delivered under the combined CPAP and PPAP are as follows:

  • Pinhalation=CPAP

  • and

  • Pexhalation=CPAP−Predetermined Pressure profile.
  • The predetermined pressure profile, which is used to reduce the CPAP pressure, has a magnitude M, which is typically selected by a respiratory therapist in a range of 0-4 cmH2O, and a duration D that, unlike the pressure curve in FIG. 7B, is not directly determined base on the patient's instantaneous flow or volume. The magnitude M represents the drop in pressure from the constant CPAP value. The duration D value is preferably a fraction of an average expiration period of the patient.
  • Multiple predefined pressure profiles, having different magnitudes, durations or both can be stored in a CPAP/PPAP device and provided to the patient. FIG. 11B illustrates three predetermined pressure profiles P1, P2 and P3, having magnitudes M1, M2 and M3 and durations D1, D2 and D3, respectively. In a preferred embodiment of the present invention, the pressure profiles are selected so that the pressure provided to the patient during exhalation roughly correspond to the contour generated from flow or volume based PPAP, as shown, for example, in FIGS. 3A and 3B. As shown in FIG. 11B, the pressure drops off quickly at the start of expiration then rises slowly toward the baseline CPAP pressure.
  • Because this embodiment for a CPAP/PPAP device does not control the flow and/or pressure provided to the patient based on the flow or pressure signal from the patient, as is the case with the PPAP devices and techniques discussed above, but instead, merely detects the start or expiration and/or inspiration, the sensor required by this embodiment need not be as accurate as in the previous embodiments. For example, a thermister or thermocouple could replace the costly pneumotach flow meter to determine the inspiratory and expiratory state. Also, the pressure profile provided to the patient during the expiratory phase can be generated using motor speed control, thereby avoiding the use of a pressure control valve.
  • While the above embodiment has been described above with respect to the use of a predetermined pressure profiled used to reduce a CPAP pressure during expiration, the same technique can be applied to a bi-level pressure support device to achieve a pressure curve shown, for example, in FIG. 8B by reducing the bi-level EPAP pressure by the predetermined pressure profile.
  • It has been observed that in some cases where PPAP is implemented and the gain is set above a certain amount, for example beyond the range of 2-3 cm/liter/sec, there is a tendency for the pressure generated by the device to become unstable. More specifically, as shown in FIG. 12, oscillations 90 occur in the pressure waveform 92 applied to the patient during portions of the patient's expiratory phase 94. These oscillations typically occur after the initial pressure drop following the onset of the expiratory phase and are believed to be generated as a result of the interaction of the patient's flow and the resulting pressure decrease.
  • Despite the chance of such oscillations occurring, it is still preferable to provide a relatively large decrease in the pressure being provided to the patient at the onset of expiration while maintaining the pressure profile as smooth as possible during the remainder of the expiratory phase. This is accomplished according to one embodiment of the present invention by providing pressure to the patient during expiration and after the maximum pressure reduction according to the following equations:

  • Pexhalation=the greater of:

  • Pbase+GainExp*Flow

  • or

  • a Current Pressure,
  • where the “Current Pressure” is the pressure being provided to the patient at that time during the expiratory phase.
  • FIG. 13 illustrates a pressure profile 92′ similar to profile 92 illustrated in FIG. 12, except that the oscillations occurring during the expiratory phase have been removed using the above described technique. For example, at point 96, which is after the maximum reduction in pressure at point 95, the pressure begins to decrease from the immediately previous pressure due to a pressure oscillation. The above oscillation prevention technique prevents this decrease by substituting the current pressure, i.e., the pressure at point 96 at all points thereafter where the calculated pressure, i.e., Pbase+GainExp*Flow, is less than the current pressure, thereby creating a plateau section 98 that corresponds to the pressure at point 96, i.e., the current pressure, until a point 100 where the calculated pressure becomes greater than the current pressure. It should be noted that for purposes of this invention Flow is considered to be negative during the expiratory phase.
  • By ensuring that the pressure provided to the patient is always the greater of the current pressure and the calculated pressure, the pressure received by the patient during expiration does not oscillate. If the pressure to be provided to the patient begins to decrease below the current pressure, the device will not use the calculated pressure, but will continue to provide the patient with the current pressure, thereby preventing a pressure decrease below the current pressure.
  • It can happen, however, that after a first minimum flow is reached, the flow will again drop below that first minimum. For example, FIG. 15 illustrates an example where the patient flow reaches a first minimum in region 150, increases in region 152 and then falls below the first minimum in region 154. If this occurs, the pressure to be delivered to the patient should not be clamped at the current pressure Pcurrent. Instead, the pressure to be delivered should be calculated using the PPAP technique, i.e., Pexhalation=Pbase+GainExp*Flow. Thus, in region 154, where the patent flow has again fallen to a level below the previous minimum level, the pressure delivered is calculated as Pexhalation=Pbase+GainExp*Flow. Of course, the present invention contemplates that Pbase can be a CPAP or IPAP pressure, as noted above.
  • In a second embodiment of the present invention, the pressure oscillations are avoided by using an entirely different calculation for determining the pressure to be provided to the patient during the expiratory phase. Instead of basing the calculation of the pressure to be provided to the patient based on the patient flow multiplied by a gain, which is selected either manually or automatically, as in the previous embodiments, the calculation of the pressure to be provided to the patient is based on the volume of gas still contained in the lungs, referred to as the volume to be exhaled. The volume to be exhaled corresponds to a difference between a current volume of gas in the patient and a volume of gas in the patient at rest. The volume of gas currently in the lungs can be readily estimated from the flow signal. The volume of gas in the patient at rest is determined using conventional techniques, and can be updated on a periodic base to ensure the accuracy of the calculation.
  • According to this embodiment, the pressure output by the PPAP device at least during a portion of the expiratory phase is described by the following function, which can be encoded into the PPAP circuitry:

  • Pexhalation=Pbase−(Volumeto be exhaled*GainExp)
  • where:
    “Pbase” is the base line pressure (greater than or equal to zero and conceptually equal to EPAP);
    “Volumeto be exhaled” is the difference between the current volume of gas in the patient less the volume of gas in the patient at rest; and
    “GainExp” is the constant used during expiration (negative flow) to reduce pressure.
  • The pressure output during the inspiratory phase is determined using the techniques discussed above. FIG. 14 illustrates a pressure curve 102 generated using the above equation to determine the pressure to be provided to the patient. It can be appreciated from FIG. 14 that pressure curve 102 accomplishes the functions of lowering the pressure during expiration and returning the pressure to the baseline at the end of the expiratory phase, preventing airway collapse.
  • Because the volume of gas to be exhaled (Volumeto be exhaled) is relatively large at the onset of the expiratory phase, the pressure drop at the beginning of exhalation can be quite large. It is preferable to smooth the large drop at the onset of the expiratory phase by including a dampening factor in the calculation of the pressure to be provided to the patient.
  • There are many techniques that can be used to dampen the initial pressure drop at the start of the expiratory phase. However, according to a preferred embodiment of the present invention, the pressure provided to the patient during the expiratory phase is described according to the following equation:
  • from the start of the expiratory phase (t0) to X:
  • Pexhalation = Pbase - t X ( Volume to be exhaled * Gain Exp )
  • and from X to the end of the expiratory phase (t1):

  • Pexhalation=Pbase−(Volumeto be exhaled*GainExp)
  • where:
    “t” is a current time following the start of the expiratory phase; and
    “X” is a predetermined transition point after the start of the expiratory phase determined by time, or analysis of the flow signal, such as curvature, percent drop from peak flow rate, integration, derivative, analysis of prior breaths or a combination of flow analysis and time.
  • As shown in FIG. 14, the value of X is chosen so that the pressure provided to the patient during the initial period from t0 to X is calculated taking into consideration the dampening factor t/X, thereby reducing the pressure drop at the onset of exhalation. Thereafter, the dampening factor is not taken into consideration and the exhalation pressure to be applied to the patient is calculated according to the second of the above two equations. Thus, this embodiment of the present invention provides a smooth pressure curve throughout the expiratory phase while ensuring that the initial pressure drop at the start of the exhalation is within expectable parameters.
  • It is to be understood that any other dampening technique for smoothing the size of the initial pressure drop at the start of the expiratory phase can be used in this embodiment. Thus, the present invention is not limited to the dampening technique discussed above.
  • It can be appreciated that, in one embodiment of the present invention, the pressure to be delivered to the patient (Pinhalation, Pexhalation) determined using the above-described techniques, is substantially continuously determined during the patient's breathing cycle. Thus, the system is continuously calculating a new setpoint pressure to be delivered to the patient and controlling the pressure support system via the pressure controller to reach that setpoint pressure. In a further embodiment of the present invention, the setpoint pressures (Pinhalation, Pexhalation) determined using the above-described techniques are filtered using a low pass filter. This is done to smooth the transition from one calculated setpoint pressure to the next. In a preferred embodiment of the present invention, the low pass filter has a 50 msec time constant.
  • In a still further embodiment of the present invention, the rate of change for the setpoint pressure delivered to the patient is monitored and controlled to prevent sharp changes in the delivered pressure. During PPAP therapy, the limits on rate of change of the setpoint are limited to keep changes in the pressure to be delivered to the patient more comfortable for the patient. Rapid changes in the setpoint pressure may impact the patient's natural waveform. By limiting this impact, the result is a more comfortable therapy, especially in the PPAP-CPAP combination. In addition, increasing the pressure to be delivered to the patient too quickly may cause the undesirable effect of an apparent early transition from expiration to inspiration.
  • The present invention contemplates controlling the rise rate, i.e., any increase in pressure, and/or the fall rate, i.e., any decrease in pressure, so that the rise rate and/or the fall rate is held within set limits. For example, the present invention contemplates that increases in the setpoint pressure to be delivered to the patient be made slower at the end of expiration. Thus, the rise rate is more limited at the end of the expiratory phase than the rate at which fall rate is limited at the start of the expiratory phase.
  • In an exemplary embodiment of the present invention, the rate of change is controlled as follows. For positive changes in pressure, if the current calculated setpoint pressure is greater than the previous calculated setpoint pressure plus a rise rate limit, the current setpoint pressure is set to the previous setpoint pressure plus the rise rate limit, otherwise the current calculated pressure is used as the setpoint pressure. For negative changes in pressure, if the current calculated setpoint pressure is less than the previous setpoint pressure plus a fall rate limit, the current pressure to be delivered to the patient is set to the previous setpoint pressure plus the fall rate limit. Otherwise, the calculated setpoint pressure is used. This feature of the present invention can be applied to the calculated Pinhalation setpoint pressure or the calculated Pexhalation setpoint pressure to ensure that pressure changes during either or both phase of the breathing cycle do not occur too sharply.
  • It can be appreciated that the setpoint pressure (Pinhalation or Pexhalation) need not be calculated continuously. For example, the setpoint pressure can be calculated using the above-described PPAP techniques during different stages of the respiratory cycle. In which case, filtering other rate of change control techniques can be used to smooth the transition from one setpoint pressure to the next.
  • Although the invention has been described in detail for the purpose of illustration based on what is currently considered to be the most practical and preferred embodiments, it is to be understood that such detail is solely for that purpose and that the invention is not limited to the disclosed embodiments, but on the contrary, is intended to cover modifications and equivalent arrangements that are within the spirit and scope of the appended claims.

Claims (12)

1. A method of delivering pressurized gas to an airway of a patient, comprising the steps of:
providing a gas flow generator and a patient interface adapted to couple the gas flow generator to an airway of a patient;
delivering a flow of gas to such a patient using the gas flow generator and the patient interface;
determining that the patient is experiencing an apnea;
performing a pressure change maneuver responsive to determining that the patient is experiencing the apnea, wherein the pressure change maneuver includes increasing a pressure of the flow of gas for a period of time, and decreasing the pressure of the flow of gas after the pressure increase;
monitoring a change in flow rate for the flow of gas resulting from the pressure change maneuver; and
determining whether the airway of the patient is open or closed based on the monitored change in the flow rate.
2. The method of claim 1, further comprising increasing the pressure of the flow of gas delivered to the patient in response to determining that the airway of the patient is closed.
3. The method of claim 1, wherein the step of delivering the flow of gas to the patient includes generating a flow of gas using a blower, and wherein the step of increasing the pressure of the flow of gas includes changing an operating speed of the blower.
4. The method of claim 1, wherein the step of delivering a flow of gas to the patient includes generating a flow of gas using an blower, and wherein the step of increasing the pressure of the flow of gas comprises: (a) controlling a pressure controller valve provided downstream of the blower, (b) changing an operating speed of such a blower, or (c) controlling the valve and changing an operating speed of the blower.
5. The method of claim 1, wherein the step of delivering the flow of gas to the patient comprises:
differentiating between an expiratory phase and an inspiratory phase of a respiratory cycle of the patient;
establishing a reduced pressure profile for a pressure of the flow of gas provided to the patient, wherein the reduced pressure profile has a contour that is predetermined prior to initiation of the expiratory phase, and wherein the contour defines a changing pressure over a period of time; and
controlling the gas flow delivered to the patient so that (1) the pressure of the flow of gas is provided at a first pressure level during at least a portion of the inspiratory phase, and (2) the pressure of the flow of gas is provided according to the reduced pressure profile during at least a portion of the expiratory phase of the respiratory cycle.
6. The method of claim 1, further comprising selecting a first gain, and wherein the step of delivering the flow of gas to the patient comprises:
monitoring a characteristic associated with the flow of gas; and
controlling the flow of gas such that the flow of gas is delivered to the patient at (1) a therapy pressure during at least a portion of an inspiratory portion of a respiratory cycle, wherein the therapy pressure is a pressure sufficient to counter airway collapsing forces, and (2) based on the first gain and the monitored characteristic during at least a portion of an expiratory phase of a respiratory cycle
7. An apparatus adapted to deliver a flow of gas to an airway of a patient, the apparatus comprising:
(a) a gas flow generator adapted to generate a flow of gas;
(b) a conduit adapted to carry the flow of gas generated by the gas flow generator to the airway of the patient;
(c) a sensor coupled to the gas flow generator or the conduit and adapted to monitor a characteristic associated with the flow of gas; and
(d) a processor adapted to:
(1) determine that the patient is experiencing an apnea based on an output of the sensor,
(2) control the gas flow generator so as to increase a pressure of the flow of gas for a period of time responsive to determining that the patient is experiencing the apnea, and to decrease the pressure of the flow of gas after the pressure increase,
(3) monitor a change in flow rate for the flow of gas based on the pressure increase, and
(4) determine whether the airway of the patient is open or closed based on the monitored change in flow rate.
8. The apparatus of claim 7, wherein the processor is further adapted to control the gas flow generator so as to increase the pressure of the flow of gas delivered to the patient in response to determining that the airway of the patient is closed.
9. The apparatus of claim 7, wherein the gas flow generator is a blower, and wherein the increases in the pressure of the flow of gas includes changing an operating speed of the blower.
10. The apparatus of claim 7, wherein the gas flow generator is a blower, and wherein the increase in the pressure of the flow of gas comprises: (a) controlling a pressure controller valve provided downstream of the blower, (b) changing an operating speed of such a blower, or (c) controlling the valve and changing an operating speed of the blower.
11. The apparatus of claim 7, wherein the processor is adapted to:
differentiate between an expiratory phase and an inspiratory phase of a respiratory cycle of the patient;
establish a reduced pressure profile for a pressure of the flow of gas provided to the patient, wherein the reduced pressure profile has a contour that is predetermined prior to initiation of the expiratory phase, and wherein the contour defines a changing pressure over a period of time; and
control the gas flow delivered to the patient so that (1) the pressure of the flow of gas is provided at a first pressure level during at least a portion of the inspiratory phase, and (2) the pressure of the flow of gas is provided according to the reduced pressure profile during at least a portion of the expiratory phase of the respiratory cycle.
12. The apparatus of claim 7, further comprising an input device adapted to select a first gain, and wherein the processor is adapted to:
monitor a characteristic associated with the flow of gas based on an output of the sensor; and
control the gas flow generator so that the flow of gas is delivered to the patient at (1) a therapy pressure during at least a portion of an inspiratory portion of a respiratory cycle, wherein the therapy pressure is a pressure sufficient to counter airway collapsing forces, and (2) based on the first gain and the output of the sensor during at least a portion of an expiratory phase of a respiratory cycle.
US12/905,230 1994-06-03 2010-10-15 Method and apparatus for providing positive airway pressure to a patient Abandoned US20110036352A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/905,230 US20110036352A1 (en) 1994-06-03 2010-10-15 Method and apparatus for providing positive airway pressure to a patient

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US08/253,496 US5535738A (en) 1994-06-03 1994-06-03 Method and apparatus for providing proportional positive airway pressure to treat sleep disordered breathing
US08/679,898 US5794615A (en) 1994-06-03 1996-07-15 Method and apparatus for providing proportional positive airway pressure to treat congestive heart failure
US09/041,195 US6105575A (en) 1994-06-03 1998-03-12 Method and apparatus for providing positive airway pressure to a patient
US09/610,733 US6609517B1 (en) 1994-06-03 2000-07-06 Method and apparatus for providing positive airway pressure to a patient
US10/304,590 US6932084B2 (en) 1994-06-03 2002-11-26 Method and apparatus for providing positive airway pressure to a patient
US11/182,387 US7296573B2 (en) 1994-06-03 2005-07-15 Method and apparatus for providing positive airway pressure to a patient
US11/926,867 US7810496B2 (en) 1994-06-03 2007-10-29 Method and apparatus for providing positive airway pressure to a patient
US12/905,230 US20110036352A1 (en) 1994-06-03 2010-10-15 Method and apparatus for providing positive airway pressure to a patient

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/926,867 Continuation US7810496B2 (en) 1994-06-03 2007-10-29 Method and apparatus for providing positive airway pressure to a patient

Publications (1)

Publication Number Publication Date
US20110036352A1 true US20110036352A1 (en) 2011-02-17

Family

ID=32392433

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/304,590 Expired - Lifetime US6932084B2 (en) 1994-06-03 2002-11-26 Method and apparatus for providing positive airway pressure to a patient
US11/182,387 Expired - Lifetime US7296573B2 (en) 1994-06-03 2005-07-15 Method and apparatus for providing positive airway pressure to a patient
US11/926,885 Abandoned US20080053443A1 (en) 1994-06-03 2007-10-29 Method and Apparatus for Providing Positive Airway Pressure to a Patient
US11/926,867 Expired - Fee Related US7810496B2 (en) 1994-06-03 2007-10-29 Method and apparatus for providing positive airway pressure to a patient
US11/929,127 Abandoned US20080053444A1 (en) 1994-06-03 2007-10-30 Method and Apparatus for Providing Positive Airway Pressure to a Patient
US12/905,230 Abandoned US20110036352A1 (en) 1994-06-03 2010-10-15 Method and apparatus for providing positive airway pressure to a patient

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US10/304,590 Expired - Lifetime US6932084B2 (en) 1994-06-03 2002-11-26 Method and apparatus for providing positive airway pressure to a patient
US11/182,387 Expired - Lifetime US7296573B2 (en) 1994-06-03 2005-07-15 Method and apparatus for providing positive airway pressure to a patient
US11/926,885 Abandoned US20080053443A1 (en) 1994-06-03 2007-10-29 Method and Apparatus for Providing Positive Airway Pressure to a Patient
US11/926,867 Expired - Fee Related US7810496B2 (en) 1994-06-03 2007-10-29 Method and apparatus for providing positive airway pressure to a patient
US11/929,127 Abandoned US20080053444A1 (en) 1994-06-03 2007-10-30 Method and Apparatus for Providing Positive Airway Pressure to a Patient

Country Status (7)

Country Link
US (6) US6932084B2 (en)
EP (1) EP1565224B1 (en)
JP (1) JP4426462B2 (en)
AU (1) AU2003295925B2 (en)
BR (1) BR0316705B1 (en)
CA (1) CA2507254C (en)
WO (1) WO2004047621A2 (en)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080058665A1 (en) * 2006-08-24 2008-03-06 Bernhard Scholler Device and method for detecting obstructive events
US8136527B2 (en) 2003-08-18 2012-03-20 Breathe Technologies, Inc. Method and device for non-invasive ventilation with nasal interface
US20130019868A1 (en) * 2006-08-30 2013-01-24 Resmed Limited Determination of leak during cpap treatment
US8381729B2 (en) 2003-06-18 2013-02-26 Breathe Technologies, Inc. Methods and devices for minimally invasive respiratory support
US8418694B2 (en) 2003-08-11 2013-04-16 Breathe Technologies, Inc. Systems, methods and apparatus for respiratory support of a patient
US8567399B2 (en) 2007-09-26 2013-10-29 Breathe Technologies, Inc. Methods and devices for providing inspiratory and expiratory flow relief during ventilation therapy
US8677999B2 (en) 2008-08-22 2014-03-25 Breathe Technologies, Inc. Methods and devices for providing mechanical ventilation with an open airway interface
US8770193B2 (en) 2008-04-18 2014-07-08 Breathe Technologies, Inc. Methods and devices for sensing respiration and controlling ventilator functions
US8776793B2 (en) 2008-04-18 2014-07-15 Breathe Technologies, Inc. Methods and devices for sensing respiration and controlling ventilator functions
US8844526B2 (en) 2012-03-30 2014-09-30 Covidien Lp Methods and systems for triggering with unknown base flow
US8925545B2 (en) 2004-02-04 2015-01-06 Breathe Technologies, Inc. Methods and devices for treating sleep apnea
US8939152B2 (en) 2010-09-30 2015-01-27 Breathe Technologies, Inc. Methods, systems and devices for humidifying a respiratory tract
US8955518B2 (en) 2003-06-18 2015-02-17 Breathe Technologies, Inc. Methods, systems and devices for improving ventilation in a lung area
US8985099B2 (en) 2006-05-18 2015-03-24 Breathe Technologies, Inc. Tracheostoma spacer, tracheotomy method, and device for inserting a tracheostoma spacer
US9022031B2 (en) 2012-01-31 2015-05-05 Covidien Lp Using estimated carinal pressure for feedback control of carinal pressure during ventilation
US9132250B2 (en) 2009-09-03 2015-09-15 Breathe Technologies, Inc. Methods, systems and devices for non-invasive ventilation including a non-sealing ventilation interface with an entrainment port and/or pressure feature
US9180270B2 (en) 2009-04-02 2015-11-10 Breathe Technologies, Inc. Methods, systems and devices for non-invasive open ventilation with gas delivery nozzles within an outer tube
US9358355B2 (en) 2013-03-11 2016-06-07 Covidien Lp Methods and systems for managing a patient move
US9364624B2 (en) 2011-12-07 2016-06-14 Covidien Lp Methods and systems for adaptive base flow
US9375542B2 (en) 2012-11-08 2016-06-28 Covidien Lp Systems and methods for monitoring, managing, and/or preventing fatigue during ventilation
US9492629B2 (en) 2013-02-14 2016-11-15 Covidien Lp Methods and systems for ventilation with unknown exhalation flow and exhalation pressure
US9498589B2 (en) 2011-12-31 2016-11-22 Covidien Lp Methods and systems for adaptive base flow and leak compensation
US9649458B2 (en) 2008-09-30 2017-05-16 Covidien Lp Breathing assistance system with multiple pressure sensors
US9925346B2 (en) 2015-01-20 2018-03-27 Covidien Lp Systems and methods for ventilation with unknown exhalation flow
US9962512B2 (en) 2009-04-02 2018-05-08 Breathe Technologies, Inc. Methods, systems and devices for non-invasive ventilation including a non-sealing ventilation interface with a free space nozzle feature
US20180133430A1 (en) * 2014-12-12 2018-05-17 Dynasthetics, Llc System and method for detection of oxygen delivery failure
US9981096B2 (en) 2013-03-13 2018-05-29 Covidien Lp Methods and systems for triggering with unknown inspiratory flow
US9993604B2 (en) 2012-04-27 2018-06-12 Covidien Lp Methods and systems for an optimized proportional assist ventilation
US10058668B2 (en) 2007-05-18 2018-08-28 Breathe Technologies, Inc. Methods and devices for sensing respiration and providing ventilation therapy
US10099028B2 (en) 2010-08-16 2018-10-16 Breathe Technologies, Inc. Methods, systems and devices using LOX to provide ventilatory support
US10252020B2 (en) 2008-10-01 2019-04-09 Breathe Technologies, Inc. Ventilator with biofeedback monitoring and control for improving patient activity and health
US10668239B2 (en) 2017-11-14 2020-06-02 Covidien Lp Systems and methods for drive pressure spontaneous ventilation
US20200360635A1 (en) * 2017-11-08 2020-11-19 General Electric Company Medical ventilator system and method for providing respiratory support to a patient
US11517691B2 (en) 2018-09-07 2022-12-06 Covidien Lp Methods and systems for high pressure controlled ventilation
US11844605B2 (en) 2016-11-10 2023-12-19 The Research Foundation For Suny System, method and biomarkers for airway obstruction

Families Citing this family (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050062609A9 (en) * 1992-08-19 2005-03-24 Lynn Lawrence A. Pulse oximetry relational alarm system for early recognition of instability and catastrophic occurrences
US7758503B2 (en) 1997-01-27 2010-07-20 Lynn Lawrence A Microprocessor system for the analysis of physiologic and financial datasets
US6932084B2 (en) * 1994-06-03 2005-08-23 Ric Investments, Inc. Method and apparatus for providing positive airway pressure to a patient
US8932227B2 (en) 2000-07-28 2015-01-13 Lawrence A. Lynn System and method for CO2 and oximetry integration
US9042952B2 (en) 1997-01-27 2015-05-26 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US20060161071A1 (en) 1997-01-27 2006-07-20 Lynn Lawrence A Time series objectification system and method
US20070191697A1 (en) * 2006-02-10 2007-08-16 Lynn Lawrence A System and method for SPO2 instability detection and quantification
US9521971B2 (en) 1997-07-14 2016-12-20 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6990980B2 (en) 2000-09-28 2006-01-31 Invacare Corporation Carbon dioxide-based Bi-level CPAP control
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
DE10103810A1 (en) * 2001-01-29 2002-08-01 Map Gmbh Device for supplying a breathing gas
US9053222B2 (en) 2002-05-17 2015-06-09 Lawrence A. Lynn Patient safety processor
US20050090721A1 (en) * 2001-03-19 2005-04-28 Shahzad Pirzada Weighing and pump system for a bed
EP1397068A2 (en) 2001-04-02 2004-03-17 Therasense, Inc. Blood glucose tracking apparatus and methods
US7938114B2 (en) * 2001-10-12 2011-05-10 Ric Investments Llc Auto-titration bi-level pressure support system and method of using same
US7189204B2 (en) 2002-12-04 2007-03-13 Cardiac Pacemakers, Inc. Sleep detection using an adjustable threshold
US9155855B2 (en) 2002-12-06 2015-10-13 Fisher & Paykel Healthcare Limited Mouthpiece
EP1605998A1 (en) * 2003-03-17 2005-12-21 MAP Medizin-Technologie GmbH Method and arrangement for the titration of physiological measuring signals in conjunction with the observation of a patient in terms of sleep-related respiratory problems
US7717112B2 (en) * 2003-06-04 2010-05-18 Jianguo Sun Positive airway pressure therapy management module
US20040244807A1 (en) * 2003-06-04 2004-12-09 Jianguo Sun Sleep-lab systems and methods
DE10337138A1 (en) * 2003-08-11 2005-03-17 Freitag, Lutz, Dr. Method and arrangement for the respiratory assistance of a patient as well as tracheal prosthesis and catheter
AU2003903138A0 (en) * 2003-06-20 2003-07-03 Resmed Limited Method and apparatus for improving the comfort of cpap
US7152598B2 (en) 2003-06-23 2006-12-26 Invacare Corporation System and method for providing a breathing gas
US7662101B2 (en) 2003-09-18 2010-02-16 Cardiac Pacemakers, Inc. Therapy control based on cardiopulmonary status
EP2008581B1 (en) 2003-08-18 2011-08-17 Cardiac Pacemakers, Inc. Patient monitoring, diagnosis, and/or therapy systems and methods
US7970470B2 (en) * 2003-09-18 2011-06-28 Cardiac Pacemakers, Inc. Diagnosis and/or therapy using blood chemistry/expired gas parameter analysis
US8606356B2 (en) 2003-09-18 2013-12-10 Cardiac Pacemakers, Inc. Autonomic arousal detection system and method
US8002553B2 (en) 2003-08-18 2011-08-23 Cardiac Pacemakers, Inc. Sleep quality data collection and evaluation
US8251061B2 (en) 2003-09-18 2012-08-28 Cardiac Pacemakers, Inc. Methods and systems for control of gas therapy
US7510531B2 (en) 2003-09-18 2009-03-31 Cardiac Pacemakers, Inc. System and method for discrimination of central and obstructive disordered breathing events
US7887493B2 (en) 2003-09-18 2011-02-15 Cardiac Pacemakers, Inc. Implantable device employing movement sensing for detecting sleep-related disorders
US7720541B2 (en) 2003-08-18 2010-05-18 Cardiac Pacemakers, Inc. Adaptive therapy for disordered breathing
US20070135724A1 (en) * 2003-10-17 2007-06-14 Ujhazy Anthony J Methods and apparatus for heart failure treatment
NZ579858A (en) * 2003-11-26 2011-02-25 Resmed Ltd Macro-control of treatment for sleep disordered breathing
CN1886169B (en) * 2003-11-26 2016-01-20 瑞思迈有限公司 The system control method that ventilation in hypopnea situation is supported and device
WO2005079726A1 (en) 2004-02-23 2005-09-01 Fisher & Paykel Healthcare Limited Breathing assistance apparatus
US7472702B2 (en) 2004-03-25 2009-01-06 Maquet Critical Care Ab Method and device responsive to diaphragmatic activity for adjusting positive pressure assist during expiration
AU2005228827C1 (en) 2004-04-02 2022-02-03 Fisher & Paykel Healthcare Limited Breathing assistance apparatus
US9072852B2 (en) 2004-04-02 2015-07-07 Fisher & Paykel Healthcare Limited Breathing assistance apparatus
US20060011195A1 (en) * 2004-07-14 2006-01-19 Ric Investments, Llc. Method and apparatus for non-rebreathing positive airway pressure ventilation
US7882834B2 (en) 2004-08-06 2011-02-08 Fisher & Paykel Healthcare Limited Autotitrating method and apparatus
US7469698B1 (en) * 2004-09-14 2008-12-30 Winthrop De Childers Parameter optimization in sleep apnea treatment apparatus
DE102005010488A1 (en) * 2005-03-04 2006-09-07 Map Medizin-Technologie Gmbh Apparatus for administering a breathing gas and method for adjusting at least temporarily alternating breathing gas pressures
EP1893265B1 (en) 2005-06-14 2013-12-04 ResMed Limited Apparatus for improving cpap patient compliance
US7918223B2 (en) * 2005-11-09 2011-04-05 Carefusion 207, Inc. System and method for circuit compliance compensated pressure-regulated volume control in a patient respiratory ventilator
US8256417B2 (en) 2005-11-23 2012-09-04 Curative (Beijing) Medical Technology Co., Ltd. Method and apparatus for providing positive airway pressure to a patient
US8015972B2 (en) 2006-01-03 2011-09-13 Shahzad Pirzada System, device and process for remotely controlling a medical device
US7706852B2 (en) * 2006-01-30 2010-04-27 Nellcor Puritan Bennett Llc System and method for detection of unstable oxygen saturation
US7668579B2 (en) * 2006-02-10 2010-02-23 Lynn Lawrence A System and method for the detection of physiologic response to stimulation
US20080027695A1 (en) * 2006-03-03 2008-01-31 Entelos, Inc. Apparatus and method for computer modeling respiratory disease
AU2007222883B2 (en) * 2006-03-06 2012-12-13 Resmed Limited Determination of apnea/hypopnea during CPAP treatment
DE102007006689B4 (en) * 2006-03-31 2021-07-29 Löwenstein Medical Technology S.A. Device and method for detecting obstruction during apnea phases by means of an additional pressure level
US7909033B2 (en) 2006-05-03 2011-03-22 Comedica Incorporated Breathing treatment apparatus
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
EP2035070B1 (en) * 2006-06-30 2019-10-30 Breas Medical AB Energy relief control in a mechanical ventilator
US7594508B2 (en) * 2006-07-13 2009-09-29 Ric Investments, Llc. Ventilation system employing synchronized delivery of positive and negative pressure ventilation
DK3738636T3 (en) 2006-07-14 2023-09-11 Fisher & Paykel Healthcare Ltd RESPIRATORY ASSIST DEVICE
US8069853B2 (en) * 2006-08-14 2011-12-06 Immediate Response Technologies Breath responsive powered air-purifying respirator
US20080060647A1 (en) * 2006-09-12 2008-03-13 Invacare Corporation System and method for delivering a breathing gas
US8051854B2 (en) 2006-09-15 2011-11-08 Comedica Incorporated Continuous high-frequency oscillation breathing treatment apparatus
WO2008048950A2 (en) * 2006-10-17 2008-04-24 Resmed Limited Device for ramped control of cpap treatment
AU2007309509B2 (en) 2006-10-24 2013-06-13 Resmed Motor Technologies Inc. Brushless DC motor with bearings
DE102006052572B3 (en) * 2006-10-30 2007-09-27 Technische Universität Dresden Pressure-supported spontaneous respiration facilitating method, involves implementing variable pressure support breathing by using variation sample of breathing way pressure in breathing device during spontaneous respiration
US20080114689A1 (en) * 2006-11-03 2008-05-15 Kevin Psynik Patient information management method
US20080114618A1 (en) 2006-11-03 2008-05-15 Kevin Pysnik Patient information management system
US8789527B2 (en) * 2007-02-12 2014-07-29 Ric Investments, Llc Pressure support system with automatic comfort feature modification
US20080216833A1 (en) 2007-03-07 2008-09-11 Pujol J Raymond Flow Sensing for Gas Delivery to a Patient
EP2144674A4 (en) * 2007-04-13 2012-12-26 Invacare Corp Apparatus and method for providing positive airway pressure
US8316849B2 (en) * 2007-04-26 2012-11-27 Buxco Electronics, Inc. Integrated ventilator with calibration
US9050434B2 (en) 2007-05-18 2015-06-09 Comedica Incorporated Lung therapy device
US8794235B2 (en) * 2007-06-08 2014-08-05 Ric Investments, Llc System and method for treating ventilatory instability
WO2009011608A1 (en) * 2007-07-19 2009-01-22 Morozov, Vasiliy Jurievich Method and device for artificial lung ventilation
CA2696773A1 (en) 2007-08-23 2009-02-26 Invacare Corporation Method and apparatus for adjusting desired pressure in positive airway pressure devices
US10076655B2 (en) 2007-09-21 2018-09-18 Koninklijke Philips N.V. Vestibular stimulation system
US20090165795A1 (en) * 2007-12-31 2009-07-02 Nellcor Puritan Bennett Llc Method and apparatus for respiratory therapy
US20090182248A1 (en) * 2008-01-15 2009-07-16 General Electric Company Systems and methods for monitoring an activity of a patient
US8275553B2 (en) 2008-02-19 2012-09-25 Nellcor Puritan Bennett Llc System and method for evaluating physiological parameter data
US7722698B2 (en) 2008-02-21 2010-05-25 Delphi Technologies, Inc. Method of determining the purity of oxygen present in an oxygen-enriched gas produced from an oxygen delivery system
US8075676B2 (en) 2008-02-22 2011-12-13 Oxus America, Inc. Damping apparatus for scroll compressors for oxygen-generating systems
US8365730B2 (en) 2008-03-24 2013-02-05 Covidien Lp Method and system for classification of photo-plethysmographically detected respiratory effort
US8640700B2 (en) 2008-03-27 2014-02-04 Covidien Lp Method for selecting target settings in a medical device
WO2009123980A1 (en) 2008-03-31 2009-10-08 Nellcor Puritan Bennett Llc System and method for determining ventilator leakage during stable periods within a breath
US8746248B2 (en) 2008-03-31 2014-06-10 Covidien Lp Determination of patient circuit disconnect in leak-compensated ventilatory support
US8267085B2 (en) 2009-03-20 2012-09-18 Nellcor Puritan Bennett Llc Leak-compensated proportional assist ventilation
US8272380B2 (en) 2008-03-31 2012-09-25 Nellcor Puritan Bennett, Llc Leak-compensated pressure triggering in medical ventilators
US8251876B2 (en) 2008-04-22 2012-08-28 Hill-Rom Services, Inc. Breathing exercise apparatus
US10258757B2 (en) 2008-05-12 2019-04-16 Fisher & Paykel Healthcare Limited Patient interface and aspects thereof
US10792451B2 (en) 2008-05-12 2020-10-06 Fisher & Paykel Healthcare Limited Patient interface and aspects thereof
US8457706B2 (en) 2008-05-16 2013-06-04 Covidien Lp Estimation of a physiological parameter using a neural network
US11660413B2 (en) 2008-07-18 2023-05-30 Fisher & Paykel Healthcare Limited Breathing assistance apparatus
US8844525B2 (en) * 2008-07-25 2014-09-30 Resmed Limited Method and apparatus for detecting and treating heart failure
US20100059059A1 (en) * 2008-09-09 2010-03-11 Perry Baromedical Corporation Hyperbaric chamber
US8398555B2 (en) 2008-09-10 2013-03-19 Covidien Lp System and method for detecting ventilatory instability
US8551006B2 (en) 2008-09-17 2013-10-08 Covidien Lp Method for determining hemodynamic effects
US10022262B2 (en) * 2008-10-02 2018-07-17 Lumen Devices Llc Palate retainer with attached nasopharyngeal airway extender for use in the treatment of obstructive sleep apnea
EP3323462B1 (en) 2008-10-10 2021-12-15 Fisher & Paykel Healthcare Limited Nasal pillows for a patient interface
AU2009324904B9 (en) 2008-11-25 2014-07-10 Lumen Devices Llc Devices, systems and methods for the treatment of sleep apnea
US8082312B2 (en) 2008-12-12 2011-12-20 Event Medical, Inc. System and method for communicating over a network with a medical device
JP5715066B2 (en) * 2008-12-19 2015-05-07 コーニンクレッカ フィリップス エヌ ヴェ System and method for treating lung disease using positive airway pressure support
EP2384211B1 (en) * 2008-12-19 2016-03-16 Koninklijke Philips N.V. System for treating lung disease using positive pressure airway support
US20140144445A1 (en) * 2009-01-08 2014-05-29 Hancock Medical Substantially Constant Positive Airway Pressure Systems and Methods for Treating Sleep Apnea, Snoring, and Other Respiratory Disorders
WO2010080709A1 (en) 2009-01-08 2010-07-15 Hancock Medical Self-contained, intermittent positive airway pressure systems and methods for treating sleep apnea, snoring, and other respiratory disorders
AU2010217315B2 (en) 2009-02-25 2014-08-21 Koninklijke Philips Electronics, N.V. Automatic pressure titration
US8424521B2 (en) 2009-02-27 2013-04-23 Covidien Lp Leak-compensated respiratory mechanics estimation in medical ventilators
US8418691B2 (en) 2009-03-20 2013-04-16 Covidien Lp Leak-compensated pressure regulated volume control ventilation
US20100288283A1 (en) * 2009-05-15 2010-11-18 Nellcor Puritan Bennett Llc Dynamic adjustment of tube compensation factor based on internal changes in breathing tube
US8985106B2 (en) * 2009-06-05 2015-03-24 Resmed Limited Methods and devices for the detection of hypopnoea
US8789529B2 (en) 2009-08-20 2014-07-29 Covidien Lp Method for ventilation
EP2473221B1 (en) 2009-09-03 2020-11-11 Breathe Technologies, Inc. Systems for non-invasive ventilation including a non-sealing ventilation interface with an entrainment port and/or pressure feature
US9151425B2 (en) 2009-11-02 2015-10-06 Comedica Incorporated Multiple conduit connector apparatus and method
JP5779186B2 (en) * 2009-11-16 2015-09-16 レスメド・リミテッドResMedLimited Method and apparatus for adaptive pressure therapy for sleep disordered breathing
US10137271B2 (en) 2009-11-18 2018-11-27 Fisher & Paykel Healthcare Limited Nasal interface
DE112010004986T5 (en) 2009-12-23 2013-01-17 Fisher & Paykel Healthcare Ltd. Patient interface and head harness
BR112012017105B1 (en) * 2010-01-14 2020-03-24 Koninklijke Philips N.V. System to deliver a flow of breathing gas to a patient's airway
WO2011086434A1 (en) * 2010-01-14 2011-07-21 Koninklijke Philips Electronics N.V. Servo ventilation using pressure drop from baseline
US8171094B2 (en) * 2010-01-19 2012-05-01 Event Medical, Inc. System and method for communicating over a network with a medical device
US8707952B2 (en) 2010-02-10 2014-04-29 Covidien Lp Leak determination in a breathing assistance system
AU2015261740B2 (en) * 2010-03-03 2016-12-08 Forschungszentrum Borstel Leibniz-Zentrum Fur Medizin Und Biowissenschaften Ventilation method and ventilation device
US8638200B2 (en) 2010-05-07 2014-01-28 Covidien Lp Ventilator-initiated prompt regarding Auto-PEEP detection during volume ventilation of non-triggering patient
US8607788B2 (en) * 2010-06-30 2013-12-17 Covidien Lp Ventilator-initiated prompt regarding auto-PEEP detection during volume ventilation of triggering patient exhibiting obstructive component
US8607789B2 (en) * 2010-06-30 2013-12-17 Covidien Lp Ventilator-initiated prompt regarding auto-PEEP detection during volume ventilation of non-triggering patient exhibiting obstructive component
US8607790B2 (en) * 2010-06-30 2013-12-17 Covidien Lp Ventilator-initiated prompt regarding auto-PEEP detection during pressure ventilation of patient exhibiting obstructive component
US8607791B2 (en) * 2010-06-30 2013-12-17 Covidien Lp Ventilator-initiated prompt regarding auto-PEEP detection during pressure ventilation
US9272105B2 (en) 2010-07-09 2016-03-01 New York University System and method for diagnosis and treatment of obstructive sleep apnea
US8676285B2 (en) 2010-07-28 2014-03-18 Covidien Lp Methods for validating patient identity
US8555880B2 (en) 2010-07-28 2013-10-15 Devilbiss Healthcare, Llc Variable transition pressure profiles for a bi-level breathing therapy machine
US8554298B2 (en) 2010-09-21 2013-10-08 Cividien LP Medical ventilator with integrated oximeter data
EP4070841A1 (en) 2010-10-08 2022-10-12 Fisher & Paykel Healthcare Limited Breathing assistance apparatus
US20120103336A1 (en) * 2010-10-29 2012-05-03 General Electric Company Ventilator System and Method
US8757153B2 (en) 2010-11-29 2014-06-24 Covidien Lp Ventilator-initiated prompt regarding detection of double triggering during ventilation
US8595639B2 (en) 2010-11-29 2013-11-26 Covidien Lp Ventilator-initiated prompt regarding detection of fluctuations in resistance
US8757152B2 (en) 2010-11-29 2014-06-24 Covidien Lp Ventilator-initiated prompt regarding detection of double triggering during a volume-control breath type
US8991392B1 (en) 2010-12-21 2015-03-31 Fisher & Paykel Healthcare Limited Pressure adjustment method for CPAP machine
WO2012085820A1 (en) * 2010-12-22 2012-06-28 Koninklijke Philips Electronics N.V. Patient monitoring and exception notification
FR2971163A1 (en) * 2011-02-07 2012-08-10 Air Liquide DEVICE FOR DETECTING INSPIRATORY FLOW LIMITATION IN A PATIENT SUFFERING FROM OBSTRUCTIVE SLEEP APNEY
US8327846B2 (en) 2011-02-08 2012-12-11 Hancock Medical, Inc. Positive airway pressure system with head position control
WO2012112783A1 (en) 2011-02-17 2012-08-23 Lumen Devices Llc Apparatus and methods for the treatment of sleep apnea
US8783250B2 (en) 2011-02-27 2014-07-22 Covidien Lp Methods and systems for transitory ventilation support
US9038633B2 (en) 2011-03-02 2015-05-26 Covidien Lp Ventilator-initiated prompt regarding high delivered tidal volume
US10603456B2 (en) 2011-04-15 2020-03-31 Fisher & Paykel Healthcare Limited Interface comprising a nasal sealing portion
CN105999504B (en) 2011-04-15 2019-09-27 费雪派克医疗保健有限公司 Interface including wrap-up bridge of the nose part
US8776792B2 (en) 2011-04-29 2014-07-15 Covidien Lp Methods and systems for volume-targeted minimum pressure-control ventilation
US8539952B2 (en) 2011-05-13 2013-09-24 Hill-Rom Services Pte. Ltd. Mechanical insufflation/exsufflation airway clearance apparatus
EP2545951B1 (en) * 2011-07-12 2021-04-07 Sefam Device for treating sleep disordered breathing
US9192795B2 (en) 2011-10-07 2015-11-24 Honeywell International Inc. System and method of calibration in a powered air purifying respirator
US9089657B2 (en) 2011-10-31 2015-07-28 Covidien Lp Methods and systems for gating user initiated increases in oxygen concentration during ventilation
US8881726B2 (en) 2011-12-27 2014-11-11 William T. Wyatt Method of relieving pain associated with fractured ribs
US9808656B2 (en) 2012-01-09 2017-11-07 Honeywell International Inc. System and method of oxygen deficiency warning in a powered air purifying respirator
US9399109B2 (en) 2012-03-02 2016-07-26 Breathe Technologies, Inc. Continuous positive airway pressure (CPAP) therapy using measurements of speed and pressure
US9180271B2 (en) 2012-03-05 2015-11-10 Hill-Rom Services Pte. Ltd. Respiratory therapy device having standard and oscillatory PEP with nebulizer
EP2822625B1 (en) 2012-03-05 2020-01-22 Keepmed Ltd Apparatus for breathing assistance
US9327089B2 (en) 2012-03-30 2016-05-03 Covidien Lp Methods and systems for compensation of tubing related loss effects
WO2013152403A1 (en) * 2012-04-13 2013-10-17 Resmed Limited Apparatus and methods for ventilatory treatment
US9027552B2 (en) 2012-07-31 2015-05-12 Covidien Lp Ventilator-initiated prompt or setting regarding detection of asynchrony during ventilation
SG10201700946YA (en) 2012-08-08 2017-03-30 Fisher & Paykel Healthcare Ltd Headgear for patient interface
EP4279106A3 (en) 2012-09-04 2024-01-17 Fisher & Paykel Healthcare Limited Valsalva mask
US9795752B2 (en) 2012-12-03 2017-10-24 Mhs Care-Innovation, Llc Combination respiratory therapy device, system, and method
US10314989B2 (en) 2013-01-28 2019-06-11 Hancock Medical, Inc. Position control devices and methods for use with positive airway pressure systems
US20160235939A1 (en) * 2013-09-05 2016-08-18 Eupnea Technologies, Inc Apparatus and method to provide breathing support
WO2015038663A1 (en) * 2013-09-10 2015-03-19 Ahmad Samir S Continuous positive airway pressure therapy target pressure comfort signature
US9675771B2 (en) 2013-10-18 2017-06-13 Covidien Lp Methods and systems for leak estimation
US9937309B2 (en) 2014-07-22 2018-04-10 Devilbiss Healthcare Llc Method of optimizing therapy pressure in a breathing therapy machine having an auto-adjust feature
US9808591B2 (en) 2014-08-15 2017-11-07 Covidien Lp Methods and systems for breath delivery synchronization
WO2016028525A1 (en) 2014-08-18 2016-02-25 Hancock Medical, Inc. Portable pap device with humidification
GB2585605B (en) 2014-08-25 2021-07-07 Fisher & Paykel Healthcare Ltd Respiratory mask and related portions, components or sub-assemblies
US10828452B2 (en) 2014-09-16 2020-11-10 Fisher & Paykel Healthcare Limited Intramold headgear
WO2016042522A1 (en) 2014-09-18 2016-03-24 Koninklijke Philips N.V. System and method for adjusting humidification during pressure support therapy
US10646680B2 (en) 2014-09-19 2020-05-12 Fisher & Paykel Healthcare Limited Headgear assemblies and interface assemblies with headgear
US9950129B2 (en) 2014-10-27 2018-04-24 Covidien Lp Ventilation triggering using change-point detection
US20160177823A1 (en) * 2014-12-22 2016-06-23 General Electric Company System and method with inlet particle separator
USD776802S1 (en) 2015-03-06 2017-01-17 Hancock Medical, Inc. Positive airway pressure system console
CN104688232B (en) * 2015-03-23 2017-12-01 北京怡和嘉业医疗科技股份有限公司 The detection method and equipment of a kind of sleep apnea
US10905836B2 (en) * 2015-04-02 2021-02-02 Hill-Rom Services Pte. Ltd. Manifold for respiratory device
TWI561261B (en) * 2015-05-08 2016-12-11 Lead Data Inc Breathing apparatus
US10518048B2 (en) 2015-07-31 2019-12-31 Hill-Rom Services, PTE Ltd. Coordinated control of HFCWO and cough assist devices
US10448899B2 (en) 2015-10-29 2019-10-22 Cardiac Pacemakers, Inc. Prediction of worsening of heart failure using blended reference
US11607518B2 (en) 2016-03-16 2023-03-21 Fisher & Paykel Healthcare Limited Directional lock for interface headgear arrangement
EP4173665A1 (en) 2016-03-16 2023-05-03 Fisher&Paykel Healthcare Limited Method for manufacturing a headgear assembly for a respiratory interface
CA3017566A1 (en) 2016-03-16 2017-09-21 Fisher & Paykel Healthcare Limited Strap assembly, strap connector, headgear, headgear assembly, method of forming headgear, tubular connector, patient interface and method of joining straps
US11433211B2 (en) 2016-03-17 2022-09-06 Zoll Medical Corporation Flow sensor for ventilation
EP3457926A4 (en) 2016-05-19 2020-09-09 Hancock Medical, Inc. Positional obstructive sleep apnea detection system
EP3338843A1 (en) * 2016-12-23 2018-06-27 Löwenstein Medical Technology S.A. Ventilation device with specification of a patient-specific pressure profile
USD823455S1 (en) 2017-02-23 2018-07-17 Fisher & Paykel Healthcare Limited Cushion assembly for breathing mask assembly
USD823454S1 (en) 2017-02-23 2018-07-17 Fisher & Paykel Healthcare Limited Cushion assembly for breathing mask assembly
USD824020S1 (en) 2017-02-23 2018-07-24 Fisher & Paykel Healthcare Limited Cushion assembly for breathing mask assembly
CN108619598B (en) * 2017-03-17 2021-07-27 深圳市大雅医疗技术有限公司 Pressure auto-titration system and method of breathing machine
JP2020519375A (en) * 2017-05-12 2020-07-02 レスメド・プロプライエタリー・リミテッド Methods and devices for the treatment of respiratory disorders
WO2018211474A1 (en) * 2017-05-19 2018-11-22 Trudell Medical International Positive expiratory pressure device
CH714047B1 (en) * 2017-08-01 2021-09-30 Christian Nirkko Arto Device for the treatment of breathing disorders by ventilatory triggering of one's own breaths by means of short pressure impulses, ramps or levels.
US10792449B2 (en) 2017-10-03 2020-10-06 Breathe Technologies, Inc. Patient interface with integrated jet pump
DE102018008620A1 (en) * 2017-11-07 2019-05-09 Löwenstein Medical Technology S.A. Apparatus for ventilation taking into account the influences of a tube
JP7234235B2 (en) * 2017-12-20 2023-03-07 コーニンクレッカ フィリップス エヌ ヴェ Control unit for use with respiratory assistance devices
US11698064B2 (en) * 2017-12-29 2023-07-11 Koninklijke Philips N.V. System and method for operating a pump in a humidifier
US11878119B2 (en) 2018-03-16 2024-01-23 Fisher & Paykel Healthcare Limited Headgear with lock disengagement mechanism
CA3099804A1 (en) 2018-05-14 2019-11-21 Covidien Lp Systems and methods for respiratory effort detection utilizing signal distortion
US11752287B2 (en) 2018-10-03 2023-09-12 Covidien Lp Systems and methods for automatic cycling or cycling detection
US11154673B2 (en) * 2018-10-17 2021-10-26 Maquet Critical Care Ab Lung recruitment in mechanical ventilation
CN109621114A (en) * 2018-12-17 2019-04-16 湖南城市学院 A kind of mechanical ventilation mode, pressure control method
US11324954B2 (en) 2019-06-28 2022-05-10 Covidien Lp Achieving smooth breathing by modified bilateral phrenic nerve pacing
WO2021136702A1 (en) * 2019-12-31 2021-07-08 Koninklijke Philips N.V. Utilizing loop gain for positive airway pressure ventilation
CN111265746B (en) * 2020-01-20 2022-02-22 深圳市科曼医疗设备有限公司 Hybrid chamber pressure control method, ventilator apparatus, and computer-readable storage medium
JP2023513051A (en) * 2020-01-29 2023-03-30 レスメド・プロプライエタリー・リミテッド Connectors for positioning and stabilizing structures
CN113133759B (en) * 2021-04-08 2023-06-16 贵州宇悦生命科技股份有限公司 Breathing auxiliary health monitoring system based on big data and use control method
USD1014517S1 (en) 2021-05-05 2024-02-13 Fisher & Paykel Healthcare Limited Display screen or portion thereof with graphical user interface

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3961627A (en) * 1973-09-07 1976-06-08 Hoffmann-La Roche Inc. Automatic regulation of respirators
US4706664A (en) * 1986-04-11 1987-11-17 Puritan-Bennett Corporation Inspiration oxygen saver
US4773411A (en) * 1986-05-08 1988-09-27 Downs John B Method and apparatus for ventilatory therapy
US4838212A (en) * 1986-10-03 1989-06-13 Morse Boulger, Inc. Superheater unit of a steam generating system
US4932402A (en) * 1986-04-11 1990-06-12 Puritan-Bennett Corporation Inspiration oxygen saver
US4938212A (en) * 1987-10-16 1990-07-03 Puritan-Bennett Corporation Inspiration oxygen saver
US4957107A (en) * 1988-05-10 1990-09-18 Sipin Anatole J Gas delivery means
US5107830A (en) * 1987-02-21 1992-04-28 University Of Manitoba Lung ventilator device
US5118098A (en) * 1987-06-11 1992-06-02 Arthur Jones Method for testing and/or exercising the rotary neck muscles of the human body
US5134995A (en) * 1989-05-19 1992-08-04 Puritan-Bennett Corporation Inspiratory airway pressure system with admittance determining apparatus and method
US5148802A (en) * 1989-09-22 1992-09-22 Respironics Inc. Method and apparatus for maintaining airway patency to treat sleep apnea and other disorders
US5161525A (en) * 1990-05-11 1992-11-10 Puritan-Bennett Corporation System and method for flow triggering of pressure supported ventilation
US5183038A (en) * 1991-11-04 1993-02-02 The Trustees Of The University Of Pennsylvania Gated programmable ventilator
US5239995A (en) * 1989-09-22 1993-08-31 Respironics, Inc. Sleep apnea treatment apparatus
US5245995A (en) * 1987-06-26 1993-09-21 Rescare Limited Device and method for monitoring breathing during sleep, control of CPAP treatment, and preventing of apnea
US5259373A (en) * 1989-05-19 1993-11-09 Puritan-Bennett Corporation Inspiratory airway pressure system controlled by the detection and analysis of patient airway sounds
US5335654A (en) * 1992-05-07 1994-08-09 New York University Method and apparatus for continuous adjustment of positive airway pressure for treating obstructive sleep apnea
US5339807A (en) * 1992-09-22 1994-08-23 Puritan-Bennett Corporation Exhalation valve stabilizing apparatus
US5353788A (en) * 1992-09-21 1994-10-11 Miles Laughton E Cardio-respiratory control and monitoring system for determining CPAP pressure for apnea treatment
US5373842A (en) * 1990-12-20 1994-12-20 Siemens Aktiengesellschaft Respirator having a trigger sensitivity dependent on the patient gas flow
US5390666A (en) * 1990-05-11 1995-02-21 Puritan-Bennett Corporation System and method for flow triggering of breath supported ventilation
US5438980A (en) * 1993-01-12 1995-08-08 Puritan-Bennett Corporation Inhalation/exhalation respiratory phase detection circuit
US5535738A (en) * 1994-06-03 1996-07-16 Respironics, Inc. Method and apparatus for providing proportional positive airway pressure to treat sleep disordered breathing
US5582163A (en) * 1993-12-06 1996-12-10 Intermed Equipamento Medico Hospitalar Ltda. Respiratory control system and apparatus
US5598838A (en) * 1995-04-07 1997-02-04 Healthdyne Technologies, Inc. Pressure support ventilatory assist system
US5645053A (en) * 1991-11-14 1997-07-08 University Technologies International, Inc. Auto CPAP system and method for preventing patient disturbance using airflow profile information
US5794615A (en) * 1994-06-03 1998-08-18 Respironics, Inc. Method and apparatus for providing proportional positive airway pressure to treat congestive heart failure
US5810759A (en) * 1997-03-27 1998-09-22 Michigan Critical Care Consultants, Inc. Control system for regulating gas exchange in extracoporeal circulation
US6105575A (en) * 1994-06-03 2000-08-22 Respironics, Inc. Method and apparatus for providing positive airway pressure to a patient

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632269A (en) * 1989-09-22 1997-05-27 Respironics Inc. Breathing gas delivery method and apparatus
JP2693620B2 (en) 1990-04-09 1997-12-24 日本石油株式会社 6-Epithioethyl-3-oxatricyclo [3.2.1. O2.4] Octane and method for producing the same
US5188098A (en) 1991-11-04 1993-02-23 The Trustees Of The University Of Pennsylvania Method and apparatus for ECG gated ventilation
US6932084B2 (en) * 1994-06-03 2005-08-23 Ric Investments, Inc. Method and apparatus for providing positive airway pressure to a patient
US6532956B2 (en) * 2000-03-30 2003-03-18 Respironics, Inc. Parameter variation for proportional assist ventilation or proportional positive airway pressure support devices

Patent Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3961627A (en) * 1973-09-07 1976-06-08 Hoffmann-La Roche Inc. Automatic regulation of respirators
US4706664A (en) * 1986-04-11 1987-11-17 Puritan-Bennett Corporation Inspiration oxygen saver
US4932402A (en) * 1986-04-11 1990-06-12 Puritan-Bennett Corporation Inspiration oxygen saver
US4773411A (en) * 1986-05-08 1988-09-27 Downs John B Method and apparatus for ventilatory therapy
US4838212A (en) * 1986-10-03 1989-06-13 Morse Boulger, Inc. Superheater unit of a steam generating system
US5107830A (en) * 1987-02-21 1992-04-28 University Of Manitoba Lung ventilator device
US5118098A (en) * 1987-06-11 1992-06-02 Arthur Jones Method for testing and/or exercising the rotary neck muscles of the human body
US20070051371A1 (en) * 1987-06-26 2007-03-08 Sullivan Colin E Method and apparatus useful in the diagnosis of obstructive sleep apnea of a patient
US5245995A (en) * 1987-06-26 1993-09-21 Rescare Limited Device and method for monitoring breathing during sleep, control of CPAP treatment, and preventing of apnea
US4938212A (en) * 1987-10-16 1990-07-03 Puritan-Bennett Corporation Inspiration oxygen saver
US4957107A (en) * 1988-05-10 1990-09-18 Sipin Anatole J Gas delivery means
US5134995A (en) * 1989-05-19 1992-08-04 Puritan-Bennett Corporation Inspiratory airway pressure system with admittance determining apparatus and method
US5259373A (en) * 1989-05-19 1993-11-09 Puritan-Bennett Corporation Inspiratory airway pressure system controlled by the detection and analysis of patient airway sounds
US5313937A (en) * 1989-09-22 1994-05-24 Respironics Inc. Leak compensation method and apparatus for a breathing system
US5148802A (en) * 1989-09-22 1992-09-22 Respironics Inc. Method and apparatus for maintaining airway patency to treat sleep apnea and other disorders
US5239995A (en) * 1989-09-22 1993-08-31 Respironics, Inc. Sleep apnea treatment apparatus
US5148802B1 (en) * 1989-09-22 1997-08-12 Respironics Inc Method and apparatus for maintaining airway patency to treat sleep apnea and other disorders
US5161525A (en) * 1990-05-11 1992-11-10 Puritan-Bennett Corporation System and method for flow triggering of pressure supported ventilation
US5390666A (en) * 1990-05-11 1995-02-21 Puritan-Bennett Corporation System and method for flow triggering of breath supported ventilation
US5373842A (en) * 1990-12-20 1994-12-20 Siemens Aktiengesellschaft Respirator having a trigger sensitivity dependent on the patient gas flow
US5551418A (en) * 1991-11-01 1996-09-03 Respironics, Inc. Sleep apnea treatment apparatus with reset circuitry
US5183038A (en) * 1991-11-04 1993-02-02 The Trustees Of The University Of Pennsylvania Gated programmable ventilator
US5645053A (en) * 1991-11-14 1997-07-08 University Technologies International, Inc. Auto CPAP system and method for preventing patient disturbance using airflow profile information
US5335654A (en) * 1992-05-07 1994-08-09 New York University Method and apparatus for continuous adjustment of positive airway pressure for treating obstructive sleep apnea
US5353788A (en) * 1992-09-21 1994-10-11 Miles Laughton E Cardio-respiratory control and monitoring system for determining CPAP pressure for apnea treatment
US5339807A (en) * 1992-09-22 1994-08-23 Puritan-Bennett Corporation Exhalation valve stabilizing apparatus
US5438980A (en) * 1993-01-12 1995-08-08 Puritan-Bennett Corporation Inhalation/exhalation respiratory phase detection circuit
US5582163A (en) * 1993-12-06 1996-12-10 Intermed Equipamento Medico Hospitalar Ltda. Respiratory control system and apparatus
US5535738A (en) * 1994-06-03 1996-07-16 Respironics, Inc. Method and apparatus for providing proportional positive airway pressure to treat sleep disordered breathing
US5794615A (en) * 1994-06-03 1998-08-18 Respironics, Inc. Method and apparatus for providing proportional positive airway pressure to treat congestive heart failure
US6105575A (en) * 1994-06-03 2000-08-22 Respironics, Inc. Method and apparatus for providing positive airway pressure to a patient
US6609517B1 (en) * 1994-06-03 2003-08-26 Respironics, Inc. Method and apparatus for providing positive airway pressure to a patient
US5598838A (en) * 1995-04-07 1997-02-04 Healthdyne Technologies, Inc. Pressure support ventilatory assist system
US5927274A (en) * 1995-04-07 1999-07-27 Healthdyne Technologies, Inc. Pressure support ventilatory assist system
US5810759A (en) * 1997-03-27 1998-09-22 Michigan Critical Care Consultants, Inc. Control system for regulating gas exchange in extracoporeal circulation

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8381729B2 (en) 2003-06-18 2013-02-26 Breathe Technologies, Inc. Methods and devices for minimally invasive respiratory support
US8955518B2 (en) 2003-06-18 2015-02-17 Breathe Technologies, Inc. Methods, systems and devices for improving ventilation in a lung area
US8418694B2 (en) 2003-08-11 2013-04-16 Breathe Technologies, Inc. Systems, methods and apparatus for respiratory support of a patient
US8136527B2 (en) 2003-08-18 2012-03-20 Breathe Technologies, Inc. Method and device for non-invasive ventilation with nasal interface
US8573219B2 (en) 2003-08-18 2013-11-05 Breathe Technologies, Inc. Method and device for non-invasive ventilation with nasal interface
US8925545B2 (en) 2004-02-04 2015-01-06 Breathe Technologies, Inc. Methods and devices for treating sleep apnea
US8985099B2 (en) 2006-05-18 2015-03-24 Breathe Technologies, Inc. Tracheostoma spacer, tracheotomy method, and device for inserting a tracheostoma spacer
US8167812B2 (en) * 2006-08-24 2012-05-01 Weinmann Gerate Fur Medizin Gmbh & Co. Kg Device and method for detecting obstructive events
US20080058665A1 (en) * 2006-08-24 2008-03-06 Bernhard Scholler Device and method for detecting obstructive events
US9408989B2 (en) 2006-08-30 2016-08-09 Resmed Limited Determination of leak during CPAP treatment
US8459260B2 (en) * 2006-08-30 2013-06-11 Resmed Limited Determination of leak during CPAP treatment
US20130019868A1 (en) * 2006-08-30 2013-01-24 Resmed Limited Determination of leak during cpap treatment
US10675424B2 (en) 2006-08-30 2020-06-09 ResMed Pty Ltd Determination of leak during CPAP treatment
US10058668B2 (en) 2007-05-18 2018-08-28 Breathe Technologies, Inc. Methods and devices for sensing respiration and providing ventilation therapy
US8567399B2 (en) 2007-09-26 2013-10-29 Breathe Technologies, Inc. Methods and devices for providing inspiratory and expiratory flow relief during ventilation therapy
US8776793B2 (en) 2008-04-18 2014-07-15 Breathe Technologies, Inc. Methods and devices for sensing respiration and controlling ventilator functions
US8770193B2 (en) 2008-04-18 2014-07-08 Breathe Technologies, Inc. Methods and devices for sensing respiration and controlling ventilator functions
US8677999B2 (en) 2008-08-22 2014-03-25 Breathe Technologies, Inc. Methods and devices for providing mechanical ventilation with an open airway interface
US9649458B2 (en) 2008-09-30 2017-05-16 Covidien Lp Breathing assistance system with multiple pressure sensors
US10252020B2 (en) 2008-10-01 2019-04-09 Breathe Technologies, Inc. Ventilator with biofeedback monitoring and control for improving patient activity and health
US9962512B2 (en) 2009-04-02 2018-05-08 Breathe Technologies, Inc. Methods, systems and devices for non-invasive ventilation including a non-sealing ventilation interface with a free space nozzle feature
US9675774B2 (en) 2009-04-02 2017-06-13 Breathe Technologies, Inc. Methods, systems and devices for non-invasive open ventilation with gas delivery nozzles in free space
US11707591B2 (en) 2009-04-02 2023-07-25 Breathe Technologies, Inc. Methods, systems and devices for non-invasive open ventilation with gas delivery nozzles with an outer tube
US10046133B2 (en) 2009-04-02 2018-08-14 Breathe Technologies, Inc. Methods, systems and devices for non-invasive open ventilation for providing ventilation support
US10232136B2 (en) 2009-04-02 2019-03-19 Breathe Technologies, Inc. Methods, systems and devices for non-invasive open ventilation for treating airway obstructions
US9227034B2 (en) 2009-04-02 2016-01-05 Beathe Technologies, Inc. Methods, systems and devices for non-invasive open ventilation for treating airway obstructions
US10709864B2 (en) 2009-04-02 2020-07-14 Breathe Technologies, Inc. Methods, systems and devices for non-invasive open ventilation with gas delivery nozzles with an outer tube
US10695519B2 (en) 2009-04-02 2020-06-30 Breathe Technologies, Inc. Methods, systems and devices for non-invasive open ventilation with gas delivery nozzles within nasal pillows
US9180270B2 (en) 2009-04-02 2015-11-10 Breathe Technologies, Inc. Methods, systems and devices for non-invasive open ventilation with gas delivery nozzles within an outer tube
US9132250B2 (en) 2009-09-03 2015-09-15 Breathe Technologies, Inc. Methods, systems and devices for non-invasive ventilation including a non-sealing ventilation interface with an entrainment port and/or pressure feature
US10265486B2 (en) 2009-09-03 2019-04-23 Breathe Technologies, Inc. Methods, systems and devices for non-invasive ventilation including a non-sealing ventilation interface with an entrainment port and/or pressure feature
US10099028B2 (en) 2010-08-16 2018-10-16 Breathe Technologies, Inc. Methods, systems and devices using LOX to provide ventilatory support
US9358358B2 (en) 2010-09-30 2016-06-07 Breathe Technologies, Inc. Methods, systems and devices for humidifying a respiratory tract
US8939152B2 (en) 2010-09-30 2015-01-27 Breathe Technologies, Inc. Methods, systems and devices for humidifying a respiratory tract
US10543327B2 (en) 2011-12-07 2020-01-28 Covidien Lp Methods and systems for adaptive base flow
US11497869B2 (en) 2011-12-07 2022-11-15 Covidien Lp Methods and systems for adaptive base flow
US9364624B2 (en) 2011-12-07 2016-06-14 Covidien Lp Methods and systems for adaptive base flow
US10709854B2 (en) 2011-12-31 2020-07-14 Covidien Lp Methods and systems for adaptive base flow and leak compensation
US11833297B2 (en) 2011-12-31 2023-12-05 Covidien Lp Methods and systems for adaptive base flow and leak compensation
US9498589B2 (en) 2011-12-31 2016-11-22 Covidien Lp Methods and systems for adaptive base flow and leak compensation
US9022031B2 (en) 2012-01-31 2015-05-05 Covidien Lp Using estimated carinal pressure for feedback control of carinal pressure during ventilation
US8844526B2 (en) 2012-03-30 2014-09-30 Covidien Lp Methods and systems for triggering with unknown base flow
US10029057B2 (en) 2012-03-30 2018-07-24 Covidien Lp Methods and systems for triggering with unknown base flow
US9993604B2 (en) 2012-04-27 2018-06-12 Covidien Lp Methods and systems for an optimized proportional assist ventilation
US10806879B2 (en) 2012-04-27 2020-10-20 Covidien Lp Methods and systems for an optimized proportional assist ventilation
US10543326B2 (en) 2012-11-08 2020-01-28 Covidien Lp Systems and methods for monitoring, managing, and preventing fatigue during ventilation
US11229759B2 (en) 2012-11-08 2022-01-25 Covidien Lp Systems and methods for monitoring, managing, and preventing fatigue during ventilation
US9375542B2 (en) 2012-11-08 2016-06-28 Covidien Lp Systems and methods for monitoring, managing, and/or preventing fatigue during ventilation
US9492629B2 (en) 2013-02-14 2016-11-15 Covidien Lp Methods and systems for ventilation with unknown exhalation flow and exhalation pressure
US10639441B2 (en) 2013-03-11 2020-05-05 Covidien Lp Methods and systems for managing a patient move
US11559641B2 (en) 2013-03-11 2023-01-24 Covidien Lp Methods and systems for managing a patient move
US9358355B2 (en) 2013-03-11 2016-06-07 Covidien Lp Methods and systems for managing a patient move
US9981096B2 (en) 2013-03-13 2018-05-29 Covidien Lp Methods and systems for triggering with unknown inspiratory flow
US20180133430A1 (en) * 2014-12-12 2018-05-17 Dynasthetics, Llc System and method for detection of oxygen delivery failure
US9925346B2 (en) 2015-01-20 2018-03-27 Covidien Lp Systems and methods for ventilation with unknown exhalation flow
US11844605B2 (en) 2016-11-10 2023-12-19 The Research Foundation For Suny System, method and biomarkers for airway obstruction
US20200360635A1 (en) * 2017-11-08 2020-11-19 General Electric Company Medical ventilator system and method for providing respiratory support to a patient
US10668239B2 (en) 2017-11-14 2020-06-02 Covidien Lp Systems and methods for drive pressure spontaneous ventilation
US11559643B2 (en) 2017-11-14 2023-01-24 Covidien Lp Systems and methods for ventilation of patients
US11517691B2 (en) 2018-09-07 2022-12-06 Covidien Lp Methods and systems for high pressure controlled ventilation

Also Published As

Publication number Publication date
CA2507254A1 (en) 2004-06-10
CA2507254C (en) 2011-08-09
US7810496B2 (en) 2010-10-12
EP1565224A4 (en) 2008-01-23
BR0316705B1 (en) 2012-12-25
WO2004047621A2 (en) 2004-06-10
US20050247315A1 (en) 2005-11-10
JP2006507873A (en) 2006-03-09
JP4426462B2 (en) 2010-03-03
US20030121519A1 (en) 2003-07-03
EP1565224B1 (en) 2012-05-23
US20080053442A1 (en) 2008-03-06
AU2003295925B2 (en) 2007-04-19
AU2003295925A1 (en) 2004-06-18
US6932084B2 (en) 2005-08-23
BR0316705A (en) 2005-10-18
US20080053444A1 (en) 2008-03-06
US7296573B2 (en) 2007-11-20
US20080053443A1 (en) 2008-03-06
EP1565224A2 (en) 2005-08-24
WO2004047621A3 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
US7810496B2 (en) Method and apparatus for providing positive airway pressure to a patient
US6609517B1 (en) Method and apparatus for providing positive airway pressure to a patient
US5794615A (en) Method and apparatus for providing proportional positive airway pressure to treat congestive heart failure
US5535738A (en) Method and apparatus for providing proportional positive airway pressure to treat sleep disordered breathing
CA2122590C (en) Sleep apnea treatment apparatus
US7770578B2 (en) Sleep apnea treatment apparatus
USRE35295E (en) Sleep apnea treatment apparatus
AU2003212056B2 (en) Method and apparatus for providing positive airway pressure to a patient
AU2004203432B2 (en) Method and apparatus for providing positive airway pressure to a patient
AU2007202185B2 (en) Method and apparatus for providing positive airway pressure to a patient

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION